

How local antibiotic use, carriage duration, resistance costs and international travel shape resistance frequency in *E. coli* in France

Olivier Cotto^{1,3}, André Birgy², Mélanie Magnan², Stéphane Béchet⁴,
Stéphane Bonacorsi², Robert Cohen⁴, Corinne Levy⁴, Forough L. Nowrouzian⁵,
Olivier Tenaillon², François Blanquart^{1,2}

Preliminary version as of April 16, 2026

1 ¹ Center for Interdisciplinary Research in Biology, CNRS, Collège de France, PSL Research
2 University, Paris, France

3 ² Université Paris Cité, IAME, INSERM, Paris, France

4 ³ PHIM Plant Health Institute, INRAE, University of Montpellier, Institut Agro, IRD, CIRAD,
5 TA A-120/K, Campus de Baillarguet, F-34398, Montpellier cedex 5, France

6 ⁴ Association Clinique Thérapeutique Infantile du Val de Marne (ACTIV), Saint Maur des
7 Fossés, France

8 ⁵ Institution of Biomedicine, Department of Infectious Diseases, University of Gothenburg,
9 Gothenburg, Sweden

10 **Keywords:** antibiotic resistance, epidemiology, *Escherichia coli*, model, Bayesian inference, costs.

11 **Abstract**

12 The worldwide rise in the prevalence of extended-spectrum beta-lactamase (ESBL) producing *Es-*
13 *cherichia coli* is a major public health concern. In Europe, ESBL carriage frequency increased then
14 stabilized at about 6-8 %. Past antibiotic use and travel in countries with high ESBL frequency,
15 notably South-East Asia, have repeatedly been identified as risk factors of ESBL carriage. Yet, the
16 relative contributions of these mechanisms to the observed maintenance of a stable low frequency
17 of ESBL in Europe remains unknown. Here, we used comprehensive data on the risk factors for
18 carriage of ESBL-producing *E. coli* in the French community, alongside detailed microbiological

19 characterization of both resistant and overall *E. coli*, to develop a biologically plausible mathe-
20 matical model of ESBL resistance spread in France. The model also includes several mechanisms
21 previously showed to favor coexistence such as population structure, variability in carriage duration
22 and within-host dynamics. The level of resistance in the community implies resistant strains trans-
23 mit 14% less than sensitive (95% credible interval 0.6-38%), and are cleared at a +23% larger rate
24 (0.9-62%). ESBL resistance is predicted to be strongly associated with factors prolonging residence
25 in the gut. Both the rate of antibiotic treatment and transmission strongly impact the frequency
26 of ESBL in the community. In contrast, travel has little impact on ESBL frequency. Whether
27 reducing treatment or transmission is best to reduce resistance depends on community-specific
28 parameters. Our study opens perspectives for the quantitative study of resistance evolution and
29 argues for future work to improve the characterization of the duration of carriage of commensal
30 bacterial strains.

31 1 Introduction

32 The worldwide rise in the prevalence of extended-spectrum beta-lactamase (ESBL) producing bac-
33 teria is a major health concern. These bacteria are resistant to many prescribed antibiotics, such
34 as penicillins or third-generation cephalosporins and are frequently co-resistant to other antibiotic
35 families like fluoroquinolones or trimethoprim/sulfamethoxazole, which leaves very few treatment
36 options upon infection. Third-generation cephalosporin-resistant *Escherichia coli* caused an esti-
37 mated 33,100 extra-deaths worldwide in 2021, making it one of the top ten deadliest pathogen-drug
38 resistance combinations (Naghavi et al., 2024).

39 Epidemiological research has provided a comprehensive understanding of the risk factors and
40 mechanisms underlying the spread of ESBL-resistant *E. coli*. While ESBL strains were initially
41 mostly found in hospitals, from 2000 onward these strains have largely spread in the community
42 as a whole (Pitout et al., 2005; Woerther et al., 2013). Frequencies of ESBL-producing *E. coli*
43 are highly heterogeneous globally. In Europe, the ESBL carriage frequency in the community
44 gently raised (Woerther et al., 2013; Bezabih et al., 2021) to stabilize from the 2010s at about 6-8
45 % (Blanquart, 2019; Bezabih et al., 2021; Castanheira et al., 2021; Pennings, 2025). In contrast,
46 ESBL carriage increased to higher levels in other countries, in particular in South-East Asia, where
47 studies commonly report a carriage of around 50%; carriage can reach values of 90% to 100% in
48 some studies (reviewed in Woerther et al., 2013; Bezabih et al., 2021; Bui et al., 2015; Jacquier

49 et al., 2023). Accordingly, in European communities, returning from South and Southeast Asia
50 is an important risk factor for the carriage of ESBL-producing Enterobacterales (Tängdén et al.,
51 2010; Kantele et al., 2015; Ruppé et al., 2015; Birgy et al., 2016; Karanika et al., 2016; Arcilla et al.,
52 2017; Hu et al., 2020; Raffelsberger et al., 2023). Based on this observation, it has been argued
53 that these travelers could potentially play an important role in shaping local levels of resistance
54 (van der Bij and Pitout, 2012; Woerther et al., 2017; Olesen et al., 2020). Additionally, past
55 antibiotic use was repeatedly identified as a risk factor for carriage of ESBL-producing *E. coli*
56 (Birgy et al., 2016; Karanika et al., 2016; Hu et al., 2020; Raffelsberger et al., 2023), as is the case
57 more generally for antibiotic-resistant bacteria (Chatterjee et al., 2018). In spite of this knowledge,
58 the relative contributions of the different mechanisms in the observed maintenance of a stable low
59 frequency of ESBL in Europe remain unknown (Emons et al., 2025).

60 Mechanistic mathematical models of resistance evolution are needed to help understand these
61 contributions and eventually develop better public health policies to reduce resistances. Models
62 are powerful tools to disentangle the role of interacting mechanisms, whether they are directly
63 observed or not, on the dynamics of resistance, and assess the impact of management strategies.
64 The impact of a reduction in antibiotic use (Lipsitch, 2001; Sundqvist et al., 2010; Blanquart et al.,
65 2017; Emons et al., 2025) and the impact of a reduction in transmission (Davies et al., 2019; Jacopin
66 et al., 2020) on resistance frequency levels both depend on modelling assumptions. For example,
67 in the case of the impact of transmission, transmission can favor the resistant strain by enabling
68 it to transmit to empty treated hosts. But it can also favor the sensitive strain by allowing it to
69 supercolonize and displace the resistant one. The end result of these two processes vary depending
70 on the assumptions on co-colonization. Thus, mechanistic models with robust assumptions are
71 needed to anticipate both future evolution and impacts of interventions.

72 Intriguingly, there are few mechanistic mathematical models of ESBL resistance evolution in
73 *E. coli* (Rahbé et al., 2024). Moreover, most of these models suffer either from assumptions that
74 are not supported by biological data, and/or from predicted behaviors that are not consistent
75 with the observed resistance dynamics. One central set of assumptions regards the description of
76 competition between strains. Competition between strains profoundly shapes resistance dynamics
77 (Lipsitch et al., 2009; Blanquart, 2019; Davies et al., 2019). It is biologically intuitive that strains
78 of the same species that only differ in their resistance status should occupy the same niche in
79 their host, and thus compete for nutrient or space. This has been recently shown for *E. coli* in

80 multiple datasets (Morel-Journel et al., 2025): *E. coli* strains are cleared faster when several strains
81 compete simultaneously in the host. Moreover, ESBL resistant strains are most often coexisting
82 with sensitive strains at low density (Ruppé et al., 2013; de Lastours et al., 2016). In spite of
83 these observations, half of existing models of antibiotic-resistance in *Enterobacterales* describe
84 only the resistant strain (Rahbé et al., 2024) which questions the plausibility and applicability of
85 their predictions. Studies that correctly include the competition between sensitive and resistant
86 strains often do not reproduce the observed coexistence of these strains—the so-called ”coexistence
87 problem” (Lipsitch et al., 2009). Instead, models predict that either the sensitive or resistant
88 strain replaces the other in most conditions (this is the case for models in Sundqvist et al. 2010;
89 MacFadden et al. 2019; Godijk et al. 2022). A notable exception is the work of Kachalov et al.
90 (2021) on *K. pneumoniae*; they modelled the dynamics of ESBL resistance in hospitals and the
91 community and reproduced the frequency of resistance across eleven European countries.

92 The coexistence of resistant and sensitive strains at the community scale, as observed in *E.*
93 *coli*, poses a more general theoretical problem (Blanquart, 2019). Several theoretical solutions
94 have been proposed (Colijn et al., 2010), including host population structure (Cobey et al., 2017;
95 Blanquart et al., 2018), variability in the duration of carriage of bacterial strains (Lehtinen et al.,
96 2017), slow dynamics of exclusion of the resistant strains by the sensitive strain within hosts (Davies
97 et al., 2019). However, these theoretical models are either not precisely parameterized with data,
98 or the parameterization of these models with existing data fails to fully explain coexistence. This
99 failure can be explained in two ways. A first possibility is that yet unknown factors play a major
100 role in the stabilization of resistance frequencies. A second possibility is that a combination of the
101 aforementioned solutions together would explain coexistence. Parameterizing complex models is
102 difficult and requires sufficiently detailed data on a system. This might have hindered progress
103 towards a satisfactory solution combining several mechanisms.

104 In this study, we use comprehensive data on the risk factors for carriage of ESBL-producing *E.*
105 *coli* in the French community, alongside detailed microbiological characterization of both resistant
106 and overall *E. coli*, to develop a biologically plausible mathematical model of ESBL resistance
107 spread in France combining several mechanisms stabilizing coexistence. Earlier analyses identified
108 travel to South-East Asia and prior use of third-generation cephalosporins as key risk factors
109 for ESBL *E. coli* carriage, consistent with other studies (Birgy et al., 2016). Here, we use this
110 dataset extended to three more years, and additionally quantify the total Enterobacterales density

111 and the density of ESBL-producing Enterobacterales in a subset of samples. This allows us to
112 precisely model competition by inferring the prevalence of different colonization states: resistant-
113 only, sensitive-only, and co-colonization. We model both the impact of travel to countries with
114 a high prevalence of ESBL, and the impact of treatment clearing sensitive strains, with the aim
115 to reproduce the inferred risk factors for ESBL carriage. We also model the known variability
116 in carriage duration across *E. coli* strains (Östblom et al., 2011; Martinson et al., 2019; Morel-
117 Journal et al., 2023), and plausible within-host dynamics of resistant and sensitive strains (Cotto
118 et al., 2023). Thus, all in all, our study includes the main theoretical explanations for coexistence:
119 population structure, variability in the duration of carriage, and within-host dynamics. We model
120 and infer in a Bayesian framework multiple fitness costs associated with epidemiological traits such
121 as transmission and clearance of resistant strains. We verify the goodness-of-fit of our model and
122 finally predict how changes in the rate of travel, the transmission rate and antibiotic use influence
123 resistance levels in the community.

124 **2 Methods**

125 **2.1 Data and model structure**

126 Our main data set is an epidemiological study of ESBL-producing *E. coli* in rectal samples from
127 $N = 3443$ French children aged 6-24 months from 2010 to 2018. Rectal samples were provided
128 during visits to pediatricians on a voluntary basis. Sampling was associated with a questionnaire
129 providing information on behaviors prior to sampling, including travel and antibiotic treatment.
130 Children undergoing antibiotic treatment within 7 days before sampling were excluded from the
131 survey. All samples were screened for the ESBL-producing Enterobacterales for a total of $N = 257$
132 resistant strains found. The details of the survey can be found in Birgy et al. (2016).

133 We focused on children to benefit from an established network of pediatricians for the collection
134 of rectal samples. The literature on ESBL resistance in Europe suggests that the prevalence of this
135 resistance does not differ much between age classes. Indeed, mean estimates of ESBL prevalence
136 range from 3.5 to 7.6% in preschool children (Van den Bunt et al., 2016; Birgy et al., 2016),
137 similar to those estimated in workers and retired age classes (6-8.6 %, Nicolas-Chanoine et al.
138 2013; Reuland et al. 2016).

139 **2.1.1 Risk factors associated with ESBL carriage**

140 A previous statistical analysis of a subset of the data (from 2010 to 2015, Birgy et al. 2016)
141 revealed that children who have traveled to South-East Asia (SEA) or who have received beta-
142 lactam antibiotics within a three-months period preceding the sampling are more likely to carry
143 ESBL-producing strains. We replicated the analyses of (Birgy et al., 2016) to our extended data
144 set (2010-2018) and found similar results (Supp.Mat. S1).

145 Following the result of the statistical analysis (Birgy et al. 2016 and Supp.Mat. S1) and
146 previous results on risk factors for ESBL carriage, we modeled five compartments to describe
147 antibiotic treatment and travel to SEA (Figure 1A). The first compartment, "untreated" U counts
148 individuals who neither traveled nor used antibiotics. Individuals receive antibiotic treatment with
149 rate τ and subsequently enter compartment "treated" T . Antibiotic treatment includes all types of
150 beta-lactams (see Supp. Mat. S1). Treatment stops at rate ω and individuals enter compartment
151 "three months post-treatment" T_3 where they remain on average three months (they leave T_3 at
152 rate $\omega_3 = 1/3 \text{ month}^{-1}$). Travel to SEA was modeled similarly to antibiotic treatment. Individuals
153 travel to SEA at rate ν . While traveling, individuals are in compartment "South-East Asia" SEA
154 where they remain for a period measured by ψ^{-1} where ψ is the rate of return from travel. After
155 travel, these individuals remain in compartment "three months post South-East Asia" SEA_3 for
156 three months (they leave SEA_3 to compartment U at rate $\psi_3 = 1/3 \text{ month}^{-1}$). For mathematical
157 convenience, we assumed a standard exponential distribution residency time in T_3 and SEA_3 . For
158 simplicity, individuals can be either in compartment SEA or T , such that we did not consider
159 individuals that both traveled and used antibiotics.

160 We used the frequencies of ESBL carriers in the (observed) compartments U , SEA_3 and T_3 for
161 parameter inference (Figure 1).

162 **2.1.2 Multiple carriage**

163 We developed a structurally neutral, mixed-carriage model (sensu Davies et al., 2019) to describe
164 the epidemiological dynamics in the system of compartments described above (Figure 1C). Indi-
165 viduals can be colonized by up to two strains. We assumed that strains can be either sensitive (S)
166 or resistant (R) to beta-lactams.

167 In the initial model, we considered two strain types, R and S. After inference of the parameters
168 (see below), the model was able to reproduce the observed equilibrium, but coexistence between

169 R and S strains occurred for a narrow range of parameters and the dynamics of equilibration was
170 much slower than the observed one (presented in Supp. Mat. S7). To improve the model, we
171 introduced further genetic structuring by modelling a locus underlying within-host persistence, as
172 theory showed that variability in duration of carriage across different bacterial genotypes can be a
173 factor maintaining coexistence (Lehtinen et al., 2017). At this locus, we considered colonizer (C)
174 and persistent (P) types. Including this genetic structuring in the model was further supported by
175 recent findings in *E. coli* showing that strain types locate along a colonization-persistence trade-off
176 (Morel-Journel et al., 2025). Further, ESBL-carriage appear to be more frequent in phylogroups
177 B2, D, F and particularly in sequence type ST131 (Birgy et al., 2016), all associated with long
178 carriage time (Östblom et al., 2011; Johnson et al., 2022; Martinson et al., 2019). Overall, we
179 considered four types of strains, which are $\{S_C, S_P, R_C, R_P\}$, where the capital letter and index
180 characterize resistance to beta-lactams and gut persistence, respectively. It follows that individuals
181 can be either uncolonized (1 possibility), single colonized by one of the four strains (4 possibilities),
182 or co-colonized (fully sensitive $S_k S_l$, fully resistant $R_k R_l$, or mixed $R_k S_l$, k and l in $\{C, P\}$,
183 10 possibilities), which all together correspond to 15 possible colonization statuses. Resistance
184 corresponds to ESBL-producing strains

185 To inform the description of co-colonizations in our model, we inferred from our data what
186 fraction of hosts were uncolonized by Enterobacterales, colonized only by ESBL strains, or by
187 ESBL together with sensitive strains (Fig. 1C). To do so, among the $N = 3443$ samples, we
188 randomly selected 301 samples to measure the total density of Enterobacterales (EB) together
189 with the density of ESBL-carrying EB (Supp.Mat.S2). Samples where no EB were found were
190 considered uncolonized. Samples containing both ESBL and sensitive strains were considered as
191 mixed-carriage individuals (Fig. 1D). Lastly, samples containing only ESBL strains were considered
192 as R individuals, with either only one or two R strains. The frequencies of uncolonized and mixed-
193 carriage hosts were used for parameter inference.

194 Previous analyses showed that clearance of resistant strains occurs as an abrupt process fol-
195 lowing a potentially long period of carriage (Cotto et al., 2023). Change of within-host densities
196 of resistant and sensitive strains was not observable at the time scale of that study. Such dynam-
197 ics are a key determinant of the between-host epidemiological dynamics (Davies et al., 2019). In
198 accordance with our results, we modeled competition between resistant and sensitive strains as a
199 clearance-recolonization process (Figure 1C). Strains are occasionally cleared from the gut of their

200 hosts, thus opening opportunities for re-colonization. Strains compete to colonize new hosts and
201 reside in them (competition at the between-host scale).

202 All in all, the epidemiological dynamics is described by a system of ordinary differential equa-
203 tions (ODE) defining the changes in the frequencies $X_{j,i}$ of the 75 types of hosts, where the
204 index j is a pair in the set $\{\emptyset, S_C, S_P, R_C, R_P\}$ indicating the colonization status as defined above
205 (15 possible pairs), and the index i corresponds to one of the five epidemiological compartments
206 $\{U, T, T_3, SEA, SEA_3\}$. The full system of equations is available as an online supplementary mate-
207 rial. The model was simulated until equilibrium was reached. Comparisons between the frequencies
208 predicted by the model at equilibrium and the five statistics in the data (frequencies of ESBL in
209 U, SEA_3, T_3 and frequencies of uncolonized and mixed-carriage hosts) in a likelihood framework
210 were used to infer the parameters of interest (see below).




Figure 1: Data-driven epidemiological model. A) compartments describing host behaviors and sampling. U : individuals who did not travel nor used antibiotics, T : individuals under antibiotic treatment, SEA : individuals traveling to South-East-Asia. the subscript 3 indicates that the corresponding behavior occurred within 3 months before sampling. Only the compartments U , SEA_3 and T_3 are observed (sampled). B) ESBL frequencies in the three observed host behaviors. C) Structure of the multiple-carriage model. Hosts can be colonized by up to two strains that belong to type C or P ($i, j \in \{C, P\}$). Estimate of Enterobacteriales density in 301 samples allowed to estimate the frequency of uncolonized (thick-open) and mixed-carriage hosts (thick-red). Solid, dashed and dotted arrows represent colonization, natural clearance and antibiotic-driven clearance, respectively. D) Density of ESBL-carrying Enterobacteriales as a function of the total density of Enterobacteriales. Dark square: all Enterobacteriales in the sample carried ESBL (R carriage hosts); red-filled dots: mixed-carriage (RS) hosts. Solid, dashed and dotted lines: fraction of ESBL-carrying strains equals 100%, 10% and 1% of the total.

211 2.2 Parameters

212 2.2.1 Models for the transmission and clearance rates

213 **Transmission and clearance rates in relation to the colonization status** Transmission
 214 and clearance rates in principle depend both on the strain and the type of host. For inference, we
 215 reduced the number of parameters based on biologically plausible assumptions (Table 1). First,
 216 we modeled the transmission rate of a given strain as depending only on whether the recipient

217 host is already colonized. We note $\beta_{j_k,1}$ and $\beta_{j_k,2}$ the colonization by strain j_k of uncolonized and
218 single-colonized hosts, respectively.

219 We also simplified natural clearance rates. The clearance rate of a given strain depends on
220 whether the host is single- or co-colonized. The clearance rate from a host single-colonized by
221 strain j_k is $\gamma_{j_k,1}$. For co-colonized hosts, we assumed niche differentiation: clearance of one strain
222 is slower when it co-occurs in the host with a strain of the other type (C or P). Niche differentiation
223 between colonizer and persistent strains is measured by parameter $\epsilon \in [0, 1]$. The clearance rate
224 of strain j_k from a host co-colonized by strains j_k and i_l (with $k, l \in C, P$) is $\gamma_{j_k,2}$ if $l = k$, and
225 $\epsilon\gamma_{j_k,2}$ otherwise (i.e., clearance is reduced by a factor ϵ if the co-occurring strains are of a different
226 type). We further assumed that clearance rates are the same in all epidemiological compartments.

227 We did not explicitly model the epidemiological dynamics abroad. Instead, we modeled a
228 constant force of colonization while traveling, equal to λ_y , where y is the colonizing strain.

229 **Transmission rate from co-colonized hosts** We modeled hosts as two "spaces", each of which
230 can be colonized by a single strain. This assumption could result, for example, from the fine-scale
231 spatial structure of the niche occupied by *E. coli* in the gut (e.g. Pereira and Berry 2017). We
232 assumed that co-colonized hosts transmit twice as much as single-colonized hosts, such that the
233 transmission rate from $\{y, y\}$ -hosts is $2X_{y,y}\beta_{y,i}$ ($i \in 1, 2$). We performed an analysis of sensitivity
234 to this assumption and found that it did not affect our main conclusions (Supp.Mat.S6).

235 For simplicity, we neglected the probability of co-transmission by co-colonized hosts. Further,
236 we modeled that mixed-carriage hosts carrying both a resistant (R) and a sensitive (S) strain can
237 shed these strains at different rates, scaled by the parameter m_x . Precisely, $\{R_k, S_l\}$ -hosts transmit
238 R strains at rate $m_x\beta_{R_k,j}$ and S strain at rate $(2 - m_x)\beta_{S_l,j}$, where $j \in \{1, 2\}$ and $k, l \in \{C, P\}$.
239 Given that we expect R strains to occur at low frequency relative to S strains (Ruppé et al., 2013;
240 de Lastours et al., 2016), we assume that $m_x \in [0, 1]$. The value $m_x = 1$ corresponds to R strains
241 in mixed-carriage transmitting as much as if they were alone in the host.

242 **Transmission and clearance rates of resistant strains** The epidemiological parameters of
243 resistant strains are defined relative to those of sensitive strains through the cost parameters δ_s
244 acting on the transmission and clearance rates. The costs of resistance did not depend on whether
245 it was associated with a persistent (P) or colonizer (C) type. Given $\beta_{S_k,1}$ and $\beta_{S_k,2}$ ($k \in \{C, P\}$),
246 we distinguish the cost of resistance on colonization and super-colonization as

$$\beta_{R_k,1} = (1 - \delta_{\beta,R,1})\beta_{S_k,1}$$

$$\beta_{R_k,2} = (1 - \delta_{\beta,R,2})\beta_{S_k,2},$$

247 where $\delta_{\beta,R,1}$ and $\delta_{\beta,R,2}$ are both included in $[0, 1]$ and measure the cost of resistance on colonization
248 and super-colonization, respectively. Similarly, we assumed that resistance can reduce persistence
249 through an increased clearance rate that depends on whether the host is single- or co- colonized.
250 We modeled the clearance rates of resistant strains compared to that of sensitive strains as

$$\gamma_{R_k,1} = \gamma_{S_k,1}(1 + \delta_{\gamma,R,1})$$

$$\gamma_{R_k,2} = \gamma_{S_k,2}(1 + \delta_{\gamma,R,2})$$

251 where $\delta_{\gamma,R,1}$ and $\delta_{\gamma,R,2}$ are the costs of resistance included in $[0, \infty]$.

252 **2.2.2 Parameter estimation**

Overall, we assume that the costs of resistance can occur on transmission and clearance and that they can depend on the colonization status of the hosts. We inferred the costs of resistance that are measured by the set of parameters :

$$P_R = \{m_x, \delta_{\beta,R,1}, \delta_{\beta,R,2}, \delta_{\gamma,R,1}, \delta_{\gamma,R,2}\}.$$

253 The other parameters were directly obtained from the focal data or from data in similar com-
254 munities, as broadly described below. The details of the parameter estimation are provided in
255 Supplementary Material S3. Table 1 recapitulates the model parameters.

256 **Rates of travel to SEA and antibiotic use** These rates were directly estimated from the mean
257 per-year fraction of children traveling to SEA and having used antibiotics [including Cefpodoxime
258 N=144 (11%), Amoxicillin N=681(54%), Amoxicillin and clavulanic acid N=370 (29%), others
259 N=75 (6%)] in the three months before sampling in our epidemiological dataset.

260 **Force of infection in South-East Asia** We assumed a fixed force of new colonization by
261 sensitive and resistant strains in South-East Asia, denoted λ_S and λ_R , respectively. The value of
262 λ_R was chosen such that about 50% of travelers would be colonized by R-strains during a 20-days
263 travel (see Supp.Mat.S3). Without information on the colonization rate by S-strains during travel,
264 we assumed $\lambda_S = \lambda_R$.

265 **Epidemiological parameters of sensitive strains** Our focal data set did not allow inference
266 of the colonization and clearance rates of sensitive strains. To do so, we used data on the turnover
267 of *E. coli* strains in Swedish children from birth to 12 months old from Östblom et al. (2011).
268 We assumed this Swedish children community had similar characteristics to our focal one. The
269 analysis of these data is provided in Supplementary Material S3. These data allowed to estimate
270 the clearance rates of sensitive strains from single- and from co-colonized hosts $\gamma_{S_k,1}$ and $\gamma_{S_k,2}$,
271 for both the colonizer and persistent types ($k \in \{C, P\}$), and the niche differentiation parameter
272 ϵ (Table 1). The persistent (P) and colonizer (C) types were identified as belonging and not
273 belonging to the phylogroup B2, respectively, consistent with the results of Östblom et al. (2011).
274 We then computed the transmission rates such that strains S_C and S_P had the same R_0 (fitness)
275 and could therefore readily coexist in the community.

276 **Inference of the epidemiological cost parameters of resistant strains** We used a Bayesian
277 approach to infer the posterior distribution of the cost parameters in P_R . We formulated the
278 likelihood with five independent components, using two pieces of information derived from our focal
279 dataset. For each component, the likelihood of the observed numbers ($n_{R,i}$) is their probabilities
280 under the law $B(N_i, p_i)$ with N_i the total number of observations in component i and p_i the
281 corresponding frequency predicted by the model. First, our epidemiological data inform on the
282 frequency of resistance in compartments U ($n_{R,U} = 105, N_U = 1632$), T_3 ($n_{R,T_3} = 81, N_{T_3} = 985$)
283 and SEA_3 ($n_{R,SEA_3} = 2, N_{SEA_3} = 12$). Note that we did not consider individuals both returned
284 from travel and who used antibiotics. We additionally measured the density of Enterobacterales
285 and ESBL-producing *E. coli* on a sub-sample of the data ($N = 301$, Supp.Mat S2) to inform on
286 the overall frequency of mixed-carriage hosts X_{RS} ($n_{RS} = 15$) and uncolonized hosts X_\emptyset ($n_\emptyset = 5$).

287 Posterior distributions of the parameters were estimated using a Bayesian approach with flat
288 priors (see Table 1). The posterior distributions were sampled by MCMC using a Metropolis-
289 Hastings algorithm with adaptive sampling (Supp.Mat.S4). We ran five independent MCMC chains

290 of 250000 iterations to check convergence to the same posterior distributions. For each chain, the
291 initial conditions were drawn randomly within the prior distribution (Table 1). The effective
292 sample size and the convergence of each chain were verified using the Gelman-Rubin diagnostic
293 implemented in the R-package coda (Plummer et al. 2006). Statistics on the MCMC chains are
294 provided in Supplementary Material S5.

Table 1: Parameters of the model. Parameters to be inferred (in the set P_R) are in *italic*. In the column "Value", bracket intervals denote the ranges investigated. We used uniform prior within these ranges for the parameters in P_R . Hyphens indicate that the value of the parameters is defined by the value of the δ 's. Rate parameters are in units of months⁻¹. See also Supp.Mat. S3

Parameter	Notation	Value
<i>Fraction of R strains transmitted by RS-hosts</i>	m_x	[0,1]
Transmission rate of S_C to uncolonized hosts	$\beta_{S_C,1}$	8.74
Transmission rate of S_P to uncolonized hosts	$\beta_{S_P,1}$	3.60
Transmission rate of S_C to single-colonized hosts	$\beta_{S_C,2}$	3.50
Transmission rate of S_P to single-colonized hosts	$\beta_{S_P,2}$	1.44
Transmission rate of $R_{i \in \{C,P\}}$ to uncolonized hosts	$\beta_{R_i,1} = \beta_{S_i,1}(1 - \delta_{\beta,R,1})$	—
<i>Cost of resistance on colonization</i>	$\delta_{\beta,R,1}$	[0,1]
Transmission rate of $R_{i \in \{C,P\}}$ to single-colonized hosts	$\beta_{R_i,2} = \beta_{S_i,2}(1 - \delta_{\beta,R,2})$	—
<i>Cost of resistance on co-colonization</i>	$\delta_{\beta,R,2}$	[0,1]
Clearance of S_C from single-colonized hosts	$\gamma_{S_C,1}$	0.15
Clearance of S_P from single-colonized hosts	$\gamma_{S_P,1}$	0.06
Clearance of S_C from co-colonized hosts	$\gamma_{S_C,2}$	0.75
Clearance of S_P from co-colonized hosts	$\gamma_{S_P,2}$	0.3
Clearance of $R_{i \in \{C,P\}}$ from single-colonized hosts	$\gamma_{R_i,1} = \gamma_{S_i,1}(1 + \delta_{\gamma,R,1})$	—
<i>Cost of resistance on clearance from single-colonized hosts</i>	$\delta_{\gamma,R,1}$	[0,10]
Clearance of $R_{i \in \{C,P\}}$ from co-colonized hosts	$\gamma_{R_i,2} = \gamma_{S_i,2}(1 + \delta_{\gamma,R,2})$	—
<i>Cost of resistance on clearance from co-colonized hosts</i>	$\delta_{\gamma,R,2}$	[0,10]
Niche differentiation	ϵ	0.65
Treatment	τ	0.15
Clearance due to antibiotics	a_S	266
Inverse duration of treatment	ω	4
Three-month post treatment	ω_3	1/3
Travel rate	ν	0.002
Inverse duration of travel	ψ	1.5
Three-month post travel	ψ_3	1/3
Force of colonization by R while traveling	λ_R	1.1
Force of colonization by S while traveling	λ_S	1.1

3 Results

We first present the epidemiological data, before turning to parameter inference with the model and its sensitivity analysis. The frequency of resistance in the community was defined as the frequency of hosts who carry at least one resistant strain.

3.1 ESBL carriage

Over 2010-2018, ESBL were found in 257 of the 3443 assessed children (7.5%, 95% CI=6.7-8.4). There was no trend in the change in ESBL during the study period (black on Fig. 2), as the increase in ESBL frequency in the community occurred before that period (blue on Fig.2). The ESBL frequency was particularly stable over the period 2015-2019. Among the assessed children, 0.6 % had travelled to SEA and 37% had received antibiotics within seven to three months before enrollment. Further details are provided in tables S1 and S2.




Figure 2: ESBL carriage as a function of time. Black: ESBL frequency in the community, measured from French children during the period 2010-2018 (focal data set). Blue: ESBL frequency in outpatients in data from the European Center for Diseases prevention and Control (ECDC), available for outpatients only over the period 2002-2010. Data are mean percentages with 95% confidence intervals. The thin gray line is a logistic model with a plateau fitted to these data with least squares, with weights proportional to the number of isolates at each timepoint. The gray envelope shows the 95% confidence intervals.

3.2 Inference of the single and mixed carriage of EBSL

To inform the mixed-carriage model, we inferred the total number of Enterobacterales (mostly and hereafter *E. coli*) and the number of those carrying ESBL in a subset of 301 samples (details

309 in Supp. Mat. S2). We found that, in most cases, ESBL and non-ESBL *E. coli* co-occurred
310 in the samples (Fig. 1D). Indeed, in most ($N = 15$) of the samples containing ESBL-carrying
311 *E. coli* ($N = 18$, see Tab. S3), the estimated number of ESBL-carrying *E. coli* was lower than
312 the estimated total number of *E. coli* . In these samples, ESBL-carrying *E. coli* represented on
313 average 4.8 % of the total number of *E. coli* . In the remaining ESBL-carrying samples ($N = 3$),
314 the ESBL-carrying *E. coli* formed the majority of *E. coli* (Tab. S3). Lastly, we found five samples
315 that were apparently not colonized by any *E. coli* .

316 **3.3 Inference of the costs of resistance**

317 **Goodness of fit** Overall, after inference, the model was able to reproduce the frequencies of the
318 different types of host colonization observed in the focal data set. The distribution of the host-type
319 frequencies predicted by the model after sampling the posterior distribution falls mainly within
320 the 95% confidence interval of the observed frequencies (Fig.S10).

321 **Costs of resistance on transmission and clearance** We found that resistance is costly:
322 R-strains transmit less efficiently and are cleared faster than S-strains (Fig. 3A-D). The costs
323 of resistance depended on the colonization status of the hosts. Our model was able to infer
324 relatively precise estimates of the costs of resistance on colonization of already colonized hosts and
325 on persistence in co-colonized hosts (i.e., additional clearance). These costs must be low to explain
326 the data. Precisely, we inferred the cost on the ability to colonize already-colonized hosts ($\delta_{\beta,R,2}$)
327 at 0.14 (median = 0.12, 95% CI = 0.006-0.38, Fig. 3B); and the cost on the persistence ability in
328 co-colonized hosts ($\delta_{\gamma,R,2}$) at 0.23 (median = 0.20, 95% CI = 0.009-0.62, Fig. 3D). In other words,
329 resistant strains colonize occupied hosts at a rate reduced by -14%, and are cleared +23% faster
330 when in competition with other strains. These two costs are the most precisely inferred, because
331 they concern the most common ecological contexts in which resistant strains are encountered.

332 In contrast, the posterior distributions of the costs on transmission to uncolonized hosts and
333 clearance from single-colonized hosts were much wider. The 95% CI of the posterior distribution
334 span most of the prior distribution for the parameters $\delta_{\beta,R,1}$ and $\delta_{\gamma,R,1}$ (shadowed area in Fig. 3A
335 and C). A wide range of resistance costs on colonization of uncolonized hosts and persistence in
336 single-colonized hosts are compatible with the data.

337 **Contributions of mixed-carriage to transmission** We found that the transmission rate of
 338 a R-strain is similar when it is in mixed carriage with a S-strain and when it is alone. Indeed, we
 339 estimated that the mean transmission rate of a R-strain while in mixed carriage (m_x parameter)
 340 is 88% (median 90, 95% CI = 68-99) of that when it is alone (Fig. 3E). This is consistent with the
 341 analysis of the count data showing that the density of ESBL-carrying *E. coli* is similar in hosts
 342 colonized only by these strains and in those carrying both ESBL and non-ESBL *E. coli* (Fig. 1D).

343 Overall, given the inferred mean values of the different fitness costs of resistance, our model
 344 predicts that after stopping travel and antibiotic treatment, it would take approximately 30 (resp.
 345 60) months for the frequency of antibiotic resistance in the community to decline below 1% (resp.
 346 1/1000).




Figure 3: Posterior distribution of the five estimated parameters. For all panels : Colored curves : posterior distribution for each of the five MCMC chains. Black curve: all chains pooled. Vertical line: Mean of the distribution. Shaded area: 95% CI. A and B, costs of resistance on colonization of uncolonized $\delta_{\beta,R,1}$ and single-colonized hosts $\delta_{\beta,R,2}$, respectively. C and D, additional clearance of resistant strains from single colonized $\delta_{\gamma,R,1}$ and co-colonized hosts $\delta_{\gamma,R,2}$, respectively. E: m_x . costs of resistance on colonization and clearance. The prior distributions of all parameters are uniform on the intervals $[0,1]$, $[0,1]$, $[0,10]$, $[0,10]$, and $[0,1]$, respectively.

347 **3.4 Predictions of the model**

348 Next, we investigated the dynamical consequences of changes in key parameters of the model on
349 the frequency of resistance in the community. The reference parameter values were those of Table
350 1 completed by the means of the posterior distributions for the inferred parameters (Fig. 3).
351 Resistance frequency was mainly driven by the treatment rate and the transmission rate of *E. coli*
352 (Fig. 4A and B), but not by travel (Fig. 4A and C).

353 **Impact of the treatment rate** We predicted that a two-fold increase in the rate of antibiotic
354 treatment would result in resistance increasing from the reference equilibrium value, 0.067 (pre-
355 dicted by the model), to 0.34 (a five-fold increase). A two-fold reduction in treatment would reduce
356 resistance to 0.0031 (Fig. 4A, C, D).

357 **Impact of the transmission rate** A two-fold increase in the transmission of *E. coli* increases
358 resistance to 0.41 (a six-fold increase compared to 0.067), while a two-fold reduction reduces resis-
359 tance to 0.0026 (a 26-fold decrease compared to 0.067) (Fig. 4B, D). Interestingly, the saturating
360 shapes of the treatment-resistance and transmission-resistance relationships (Fig. 4A, B) imply
361 that for the same baseline level of resistance, reducing transmission or treatment rate could have
362 a small or large impact on the frequency of resistance (arrows on Fig. 4A, B).

363 **Impact of the travel rate** In contrast, varying the rate of travel had very little impact on
364 the equilibrium frequency of resistance (Fig. 4A, C). The only discernible impact was when the
365 treatment rate is very small, in which case resistance is counter-selected and the equilibrium
366 frequency of resistance is therefore proportional to travel (Fig. 4A inset). In population genetics
367 terms, in this parameter region resistance is maintained at a selection-migration balance.




Figure 4: Sensitivity of the frequency of resistance to the rates of treatment, transmission and travel. **A**, the frequency of resistance as a function of the treatment rate, shown for four values of the travel rate. The dashed vertical line is the reference value. The inset shows the logit-transformed resistance frequency ($\log_{10}(p_R/(1 - p_R))$) specifically in the low-treatment region, highlighting the impact of travel in these conditions. **B**, the frequency of resistance as a function of the relative transmission rate, for three values of the treatment rate. On panels **A** & **B**, the arrows highlight the effect of a change in treatment rate or transmission on resistance frequency. **C**, **D** contour plots of the frequency of resistance as a function of treatment, transmission and travel rate. The points show the reference values. When unspecified, parameters are fixed to their reference value as given in Table 1.

368 **Negative frequency-dependent selection on resistance** We investigated the frequency-
 369 dependent selection (Harmand et al., 2019) on resistance generated by our model that includes

370 a combination of mechanisms stabilizing resistance at an intermediate frequency. Our model gener-
 371 erates negative frequency-dependent selection (NFDS), as shown by the slope of the selection
 372 coefficient on resistance as a function of its frequency in Figure 5, which results in the coexis-
 373 tence of resistant and sensitive strains. The equilibrium frequency of resistance is where the curve
 374 crosses the x-axis. The selection coefficient on resistance first rapidly declines, before decreasing
 375 as the frequency of resistance increases. The initial phase of strong positive "selection" is actually
 376 driven by travel and importation of resistance from abroad. This initial increase is faster when
 377 the travel rate is high. The second phase of decline depends on the treatment and transmission
 378 rates. Increasing the treatment or the transmission rate strengthen selection in favor of resistance
 379 at large resistance frequency and consequently increases the equilibrium frequency of resistance
 380 (Fig. 5A,C).




Figure 5: Effect of the treatment rate (A), travel rate (B) and transmission rate (C) on frequency-dependent selection on resistance. Frequency-dependent selection is shown by the selection coefficient on resistance as a function of resistance frequency. The selection coefficient is measured as $s_R = d/dt(\log(p_R/(1 - p_R)))$.

381 Modeling both a colonizer and a persistent strategy strengthens NFDS compared to a model
 382 assuming a single generalist strategy with the same average fitness (Fig. 6A). We further found
 383 that when both a colonizer and a persistent strategy are implemented, resistance is associated with
 384 the persistent strategy (Fig. 6B), while sensitivity is associated with the colonizer strategy (not
 385 shown). These associations increase when differentiation along the persistence-colonization trade
 386 off increases (Fig. 6B). Overall, the NFDS generated by the occurrence of differentiated strategies
 387 on the colonization-persistence trade-off, and the non-random association of resistance with these
 388 strategies, favor the coexistence of resistant and sensitive strains in the community.




Figure 6: Effect of niche differentiation along the colonization-persistence trade-off on negative-frequency-dependent selection (NFDS). Frequency-dependent selection is shown by the slope of the selection coefficient on resistance as a function of resistance frequency. A: Comparison of NFDS produced by the (main) model with both a colonizer and a persistent strategy and that of a model with a single generalist strategy with the same fitness. In the generalist model, resistance costs (P_R) were inferred similarly to the main model. B: Association of resistance with the persistent strategy in a model assuming differentiated strategies along the persistent/colonization trade-off. The association is measured as the proportion of R_P -carrying hosts among all R -carrying hosts. Differentiation d is measured as departure from the mean strategy: $\beta_{S_C,1} = \bar{\beta}_{S,1}(1 + d)$ and $\gamma_{S_C,1} = \bar{\gamma}_{S,1}(1 + d)$ for the colonizer and opposite ($-d$) for the persistent. Other parameters as in Table 1.

389 4 Discussion

390 In Europe, the stabilization of the frequency of resistant *E. coli* at a low level after a rapid increase
391 in the early 2000s remains largely unexplained (Emons et al., 2025). Empirical and theoretical stud-
392 ies have pointed to several mechanisms that favor resistance carriage and coexistence of resistant
393 and sensitive strains in the community (Blanquart, 2019; Rahbé et al., 2024). However, how these
394 mechanisms contribute to the observed dynamics remain largely unknown. Here, we proposed a
395 data-informed epidemiological model that leverages i) a large dataset on ESBL-driven antibiotic
396 resistance in healthy infants ii) a detailed microbiological characterization of samples and iii) our
397 current knowledge of the ecology and epidemiology of *E. coli*, to gain a mechanistic understanding
398 of the evolution of ESBL-driven antibiotic resistance in the community in France.

399 It has repeatedly been reported that returning from South and Southeast Asia is a risk factor
400 for carriage of resistant strains of Enterobacterales. Although travel has been presented as an
401 important contributor to resistance in high-income countries, and measures to limit the importation
402 of resistance by travelers have been proposed (e.g., Reuland et al., 2016; Arcilla et al., 2017), the
403 actual impact of travelers on local resistance had not been quantified. This impact not only depends
404 on the rate of travel, but also on the dynamics of onward transmission of resistance by travelers
405 and the eventual clearance of resistant strains. In our model including these phenomena, we show
406 that importations have little effect on the local equilibrium ESBL frequency, except initially or
407 when the local treatment rate is very low. At the current or higher treatment rates, a 10-fold
408 increase in the rate of travel would barely change the equilibrium frequency of resistance in the
409 focal community. Our results are in line with another recent mathematical model (Rahbe et al.,
410 2025).

411 ESBL resistance must come with costs that counterbalance its advantage under treatment.
412 Costs of antibiotic resistance have often been found in *in vitro* growth assays (e.g. Melnyk et al.,
413 2015). However, experimental evidence on whether and how antibiotic resistance alters transmis-
414 sion is still missing (Andersson, 2006) and the costs in terms of epidemiological parameters have
415 not previously been quantified. Here, we modeled and inferred four costs of resistance: two costs on
416 transmission to empty and colonized hosts, and two costs on clearance in single- and co-colonized
417 hosts. We could only precisely estimate the costs of transmission to colonized hosts and clearance
418 in co-colonized hosts, which corresponds to the most frequent ecological context in which ESBL

419 *E. coli* are found. These costs were found to be relatively low (-14% and +23% on transmission
420 and clearance, respectively).

421 We also found that resistant strains transmit as much from single-colonized hosts as from
422 mixed-carriage hosts (m_x close to 1), which is consistent with our data, where resistant strains
423 reached similar density when they are alone in their host as when they are co-carried with sensitive
424 strains. The model further implies that ESBL strains cannot persist in the community if resistance
425 transmission from mixed-carriage hosts is lower than from hosts carrying the resistant strains only.

426 Overall, the relatively small cost of resistant strains in transmission in spite of substantially
427 lower density could be explained if the relationship between within-host density and transmission
428 rate is sublinear, as is the case for other pathogens where this relation was characterised (Fraser
429 et al., 2007; Duong et al., 2015; Marc et al., 2021). Such relationship could be determined for
430 ESBL resistance from household studies, but this has not yet been done to our knowledge (Arcilla
431 et al., 2017; Perez et al., 2025).

432 In our model, the frequency of ESBL is strongly determined by the rate of treatment with
433 beta-lactams. The relationship between the rate of treatment and the equilibrium level of resis-
434 tance was quite progressive, in contrast to most previous theoretical work (Blanquart, 2019; Davies
435 et al., 2019). Negative-frequency dependent selection (NFDS) is key to promote coexistence be-
436 tween resistant and sensitive strains (Davies et al., 2019). Our model with biologically plausible
437 structure and parameters was able to generate NFDS and reproduce the progressive use-resistance
438 relationship.

439 An important finding is that the variability in carriage duration, here modeled with a twice
440 longer carriage duration for strains of phylogroup B2, was the most important factor favoring
441 coexistence. Resistance preferentially evolves on the genotype with long duration of carriage in
442 our model (Fig. S8) (Lehtinen et al., 2017). This prediction was also verified to some extent
443 in our data: typing some of the resistant strains isolates from these data showed that ESBL
444 resistance was mostly confined to ST131 (phylogroup B2) (Birgy et al., 2016), a sequence type with
445 remarkably long duration of carriage (Johnson et al., 2022). Thus, the heterogeneity in duration
446 of carriage must be modeled to properly reproduce qualitative patterns in data. Other factors do
447 not generate much coexistence. The clearance-recolonization dynamics, which we modelled in line
448 with available data (Cotto et al., 2023), is poorly conducive to coexistence (Fig. S6). Lastly, travel
449 had a very limited role in stabilising coexistence: in spite of strong differentiation between France

450 and Southeast Asia, the rate of travel was too small to significantly impact equilibrium levels of
451 resistance.

452 Nevertheless, the observed coexistence and the NFDS were less strong in our model than in
453 data. Among the factors that we did not include in the model, the structure in hospital-community
454 and the acquisition of ESBL strains in hospitals may not play an important role: in broad terms,
455 hospitalization has analogous consequences to travel. In France, there are an estimated 10M
456 hospital stays per year. If about half of individuals return from hospital stays colonized by ESBL,
457 the impact of hospitalization is equivalent to the impact of travel at a rate of 0.02 per month
458 (10-fold greater rate), which is negligible. Moreover, in our data, infants with a recent hospital
459 stay did not have particularly elevated levels of resistance (Table S1). Other unobserved sources
460 of population structure could play a role in coexistence, but this would imply that a major risk
461 factor for ESBL carriage has been overlooked in the many previous studies. The last and most
462 plausible explanation in our view is that the distribution of carriage duration is variable at a finer
463 phylogenetic unit (i.e. across ST). For lack of better data, we modelled a very simple distribution
464 of carriage duration reflecting a two-fold longer carriage for B2 phylogroup vs. non-B2 phylogroup
465 as in Swedish infants (Östblom et al., 2011). The true value of this ratio was larger (4-fold) in
466 another study (Johnson et al., 2022). Modelling this distribution in more details may lead to a
467 more progressive use-resistance relationship (Lehtinen et al., 2017), stronger NFDS, and should
468 therefore be an important focus for future work.

469 We also found that increasing transmission increases the prevalence of resistance in the com-
470 munity. Importantly, the effect of transmission is nearly as strong as that of the rate of antibiotic
471 treatment. This finding is consistent with a global analysis that found that factors associated
472 with poor sanitation, but not antibiotic use, are associated with antibiotic resistance in *E. coli*
473 (Collignon et al., 2018), and other recent modelling work (Rahbe et al., 2025). Transmission fa-
474 vors colonization by resistant strains during and immediately after treatment, when competition
475 by sensitive strains is released (Blanquart et al., 2018; Davies et al., 2019). In untreated hosts,
476 increasing transmission similarly favors resistant and sensitive strains without affecting their rela-
477 tive fitness (assuming a fixed cost of resistance). Without treatment, sensitive strains increase in
478 frequency by out-competing resistant strains in the clearance-recolonization dynamic of untreated
479 hosts. Explicitly modeling treatment structure is necessary to capture how transmission favors
480 resistance (Blanquart et al., 2018) (a model without such structure predicts that transmission

481 disfavors resistance - not shown).

482 Our dataset, in spite of its very large size, focus on healthy individuals, and detailed information,
483 has some limits. We focused on healthy infants aged less than two years and use these data to
484 model the community as a whole. We note that most studies focusing on resistance in the gut
485 have to resort to convenience sampling, e.g. infants, pregnant women, hospital patients. Several
486 results support that the epidemiology of *E. coli* resistance and sensitivity weakly depends on the
487 age of the hosts. Children are very rapidly colonized by *E. coli* after birth (Palmer et al., 2007).
488 The equilibrium ESBL frequency in our data was similar to that found in other age groups in the
489 Paris area (Nicolas-Chanoine et al., 2013). Data from invasive infections collected by the European
490 Center for Disease Prevention and Control (ECDC) also does not support a strong and consistent
491 structure across age classes for *E. coli* ESBL resistance (Fig.S11). Lastly, the patterns in the data
492 that inform our inferences are robust to examining infants, children or adults. History of treatment
493 and travel as main risk factors for resistance are well established (e.g. Birgy et al., 2016), as is
494 the fact that resistant most of the time co-occurs as a minority strains within hosts (Ruppé et al.,
495 2013; de Lastours et al., 2016). Another potential limitation of our data is that children undergoing
496 antibiotic treatment within 7 days prior to the sampling were excluded from the survey. These
497 children potentially carry ESBL at higher frequency and density (Ruppé et al., 2013; de Lastours
498 et al., 2016), which would lead to underestimating the frequency of ESBL in our focal community
499 and the prevalence of individuals colonized only by resistant strains. This underestimation is likely
500 to be weak, as given the observed rate of treatment we would miss only nine infants with this
501 exclusion criterion. Accordingly, the ESBL frequency in our data is consistent with other studies
502 (e.g. Gagliotti et al., 2011; Bezabih et al., 2021).

503 Secondly, while we carefully crafted our model to include all plausible processes affecting an-
504 tibiotic resistance, some of the assumptions could be discussed. We did not specifically model
505 individuals who both travelled and used antibiotics (N=7). It is unlikely that modeling these
506 individuals would have impacted our results, given the limited role of travel that we found and
507 the model constrains some travelers to come back with ESBL. We did not include hospitalization
508 as a risk factor in our model, but as discussed above hospitalization was not a risk factor in our
509 data, and in theory cannot play a very important role. We assumed that co-colonized hosts carry
510 and transmit twice as much bacteria than single-colonized ones. Models sometimes alternatively
511 assume that the transmission rate is the same for single- and co-colonized hosts (Alizon et al.,

2013). The predictions of our model were not affected by this assumption (Fig.S3). Lastly, our model allows only weak competitive release of the resistant strain: treatment leads to clearance of the sensitive strain, and the resistant strain does not transmit more when it is alone in the host. Empirical data suggest that treatment clears a large fraction of the whole microbiota. This could allow a stronger increase in the density of resistant strains than modelled here (Ruppé et al., 2013; Niehus et al., 2020). Our predictions remain unchanged when assuming a 5-fold increase in transmission of resistance upon treatment (Fig.S4).

Our findings have several implications. The most important drivers of local resistance frequency were antibiotic use in the community and transmission, not the importation of resistant strains from Southeast Asia. Coexistence was mainly stabilized by the interaction with another locus determining the duration of carriage (Lehtinen et al., 2017). This association has several important consequences. First, it is difficult to measure a cost of resistance on strain clearance because resistance is associated with strains with long duration of carriage. To directly measure this cost, it is necessary to control for the impact of the genetic background on carriage duration (Krishna et al., 2025). Second, an intervention to decolonize resistant strains of *E. coli* should be very efficient: indeed, if resistant strains are associated with "slow-turnover" strains with long duration of carriage and low colonization rates (Morel-Journel et al., 2023), then removing these strains would severely reduce their fitness. Thirdly, novel resistances might primarily emerge first on travellers, second on long-duration of carriage genomic backgrounds. Strains with long duration of carriage could be particularly targeted for surveillance. It would thus be necessary to quantify the distribution of residence times of bacterial strains in commensalism, and understand what factors maintain this diversity, to fully understand resistance evolution.

To conclude, using one of the largest cohorts studying ESBL resistance in the community in healthy individuals, together with detailed and informed modeling of competition between sensitive and resistant strains—a critical point that has been overlooked by some previous studies—we understood mechanistically the evolution of resistance in the community in France. This points to around 10-20% costs of resistance on transmission and clearance, a major role of selection by local antibiotic use and transmission, and variability in the duration of carriage as the main factor stabilizing sensitive and resistant strains. This opens perspectives for the quantitative study of resistance evolution, most interestingly testing our prediction on the sublinear relationship between strain density and transmission (for example in household studies); and improved characterization

543 of the duration of carriage of commensal bacterial strains.

544 **5 Acknowledgments**

545 This work was funded by the CNRS Momentum grant to FB and the ERC StG 949208 to FB.

546 We are grateful to the INRAE MIGALE bioinformatics facility (MIGALE, INRAE, 2020. Mi-
547 gale bioinformatics Facility, doi: 10.15454/1.5572390655343293E12) for providing computing re-
548 sources.

549 Data for Figures 2 and S11 from The European Surveillance System—TESSy, provided by
550 Austria, Belgium, Czech Republic, Germany, Denmark, Spain, Finland, France, Hungary, Ireland,
551 Italy, Netherlands, Norway, Poland, Portugal, Sweden, Slovenia, United Kingdom, and released by
552 ECDC. The views and opinions of the authors expressed herein do not necessarily state or reflect
553 those of ECDC. The accuracy of the authors' statistical analysis and the findings they report
554 are not the responsibility of ECDC. ECDC is not responsible for conclusions or opinions drawn
555 from the data provided. ECDC is not responsible for the correctness of the data and for data
556 management, data merging and data collation after provision of the data. ECDC shall not be held
557 liable for improper or incorrect use of the data.

558 6 Supplementary material

559 S1 Statistical analysis

560 **Summary of the full data set** 3443 rectal samples from French children aged 6-24 months
561 have been collected from 2010 to 2018, corresponding to 3417 different individuals. Sampling was
562 associated with a questionnaire. Information so gathered is fully described in (Birgy et al., 2016).

563 Birgy et al. (2016) further analyzed the risk factors associated with ESBL carriage (based on
564 samples obtained during the 2010-2015 period). In particular, a multivariate analysis identified
565 home care, the use antibiotics and the travel history within three months prior to sampling as the
566 main risk factors related to ESBL carriage. Furthermore, univariate analyses identified travel to
567 Oceania/Asia as the only region associated with a significant increase in the risk of ESBL carriage
568 (Birgy et al., 2016).

569 In the present study, we focused on the risk factors related to ESBL carriage corresponding
570 to i) travel to Asia/Oceania, hereafter Southeast Asia [SEA], and ii) the use of antibiotics, both
571 within three months prior to sampling (Table S1). We extended the analyses of Birgy et al. (2016)
572 to the period 2010-2018 and found similar results (Table S2).

Table S1: Contingency table for the number of occurrences of each risk factor considered in the model

		Used antibiotics three month before sampling	
		0	1
Traveled to SEA three month before sampling	0	2150	1268
	1	12	7

Table S2: Analysis of risk factors associated with ESBL carriage (extended from Birgy et al. 2016 to the period 2010-2018) ; overall samples N = 3443, carriage of ESBL = 257 (7.4%). The univariate analysis was performed using χ -square tests. For the multivariate analysis, we kept only the most significant factors of the univariate analyses (P<0.2). Children who did not travel were pooled with those who travelled to western/northern Europe. In the multivariate analysis, we considered only the children with information on travel history (2012-2018).

	Univariate analysis		Multivariate analysis		
	n (%)	P	aOR	95% CI	P
Sex		0.063			
male	123 (48)		0.74	0.54-1.01	0.055
female	134 (52)		1		
Age		0.027			
< 12 months	105 (41)		1		
≥ 12 months	152 (59)		1.24	0.91-1.7	0.17
Preterm		0.90			
no	169 (93)				
yes	12 (7)				
Caesarean		0.11			
no	136 (75)		1		
yes	45 (25)		1.33	0.92-1.89	0.11
Daycare modality		0.022			
child minder	56 (22)		0.68	0.45-1.02	0.07
home	73 (28)		1.14	0.77-1.65	0.50
daycare center	128 (50)		1		
Siblings		0.53			
no	124 (48)				
yes	132 (52)				
Recent use of antibiotics		0.045			
no	146 (57)		1		
yes	110 (43)		1.26	0.90-1.73	0.16
oral 3rd gen. cephalosporin	18 (17)				
amoxicillin	54 (49)				
amoxicillin/clavulanate	29 (27)				
other	8 (7)				
Hospitalization in the last 6 months		0.59			
no	228				
yes	13				
Hospitalization since birth		0.63			
no	203 (95)				
yes	38 (5)				
Travel history (data from 2012)		0.05			
no	155 (57)		1		
unknown	16 (19)				
yes	86 (24)		1.24	0.90-1.71	0.18
African/Mediterranean region	49 (82)				
America	0 (0)				
Asia/Oceania	5 (8)				
western/northern Europe	6 (10)				

573 **S2 Density of resistant and sensitive *E. coli* strains in mixed-carriage**
574 **hosts**

575 Among the above samples (years 2014-2016), 301 were further analyzed to evaluate the total
576 density of Enterobacterales (EB) and the density of ESBL-carrying *E. coli* strains. Density has

577 been estimated using dilution counts (by a factor 10^{-1} to 10^{-6}) on selective media (Drigalski for
 578 Enterobacteriales and ESBL-selective). There was five samples where no EB were detected.

We further assumed that the number of bacteria in each sample followed a Poisson distribution. The Maximum Likelihood estimator for the number of bacteria is then

$$\hat{\eta} = \frac{\sum_i k_i}{\sum_i d_i},$$

579 where d_i is the dilution factor and k_i is the number of bacteria counted at dilution d_i .

580 For each sample where EB were found, we then compared two models using a AIC criterion
 581 (i.e. $\Delta AIC \geq 2$): i) $\eta_{EB} = \eta_{ESBL}$ (all EB carry ESBL genes), ii) $\eta_{EB} \neq \eta_{ESBL}$ (some EB carry
 582 ESBL genes). The results are presented on table S3.

Table S3

$\eta_{EB} = 0$	$\hat{\eta}_{ESBL} = 0$	$\hat{\eta}_{EB} > \eta_{ESBL}$	$\hat{\eta}_{EB} = \hat{\eta}_{ESBL}$	$\hat{\eta}_{EB} < \hat{\eta}_{ESBL}$
5	278	15	1	2

583 We found five samples without EB cells (Tab. S3). In most samples with ESBL strains, ESBL
 584 strains co-occurred with sensitive strains. We found three samples where all EB carried ESBL,
 585 including two samples in which the number of EB cells carrying ESBL was estimated to be larger
 586 than the total number of EB cells, probably due to measurement error. Figure S1 shows the
 587 distribution of the relative ESBL density. We found that in most cases, ESBL density represents
 588 more than 1% of the total EB density (30% quantile at 1% and mean at 17%). In our likelihood
 589 calculation, we considered that hosts with $\hat{\eta}_{EB} > \eta_{ESBL}$ belonged to type "RS", and we used the
 590 number of uncolonized hosts $\eta_{EB} = 0$ (see main text).




Figure S1: Distribution of the relative ESBL density

591 S3 Parameters

592 We provide here the methods used to obtain the parameter values that are not inferred with the
 593 model.

594 **Treatment rate** In the focal data set, on average 37% (min 33%, max 43% depending of the
 595 year) of children received antibiotics within three months before sampling. The number of children

596 starting an antibiotic treatment during a given time period follows a Poisson process. The elapsed
597 time T between the end of the treatment and the sampling follows an exponential law of parameter
598 τ . The probability that the sampling occurs during a three-month period after treatment is $P(T \leq$
599 $3) = 1 - e^{-3\tau} = 0.37$. Solving for this equation, we find $\tau = 0.15 m^{-1}$. The rate at which the event
600 "sampling occurs within three months after treatment" occurs is equal to the rate of occurrence
601 of "starting an antibiotic treatment", such that τ is the treatment rate.

602 **Duration of the treatment** The typical duration of antibiotic treatments is one week (Spellberg
603 and Rice, 2019), corresponding to a monthly rate of $4 m^{-1}$.

604 **Antibiotic efficiency** We used results from Paterson et al. (2016) who investigated the opti-
605 mal antibiotic concentration to cure bacterial infection. Using their typical values for antibiotic
606 concentration ($23 \mu g.L^{-1}$) and sensitive strains in their equation 5, we find an approximate death
607 rate due to antibiotics of $8.6 d^{-1}$ in their original scaling, corresponding to $266 m^{-1}$.

608 **Post-treatment period** By choosing $\omega_3 = 1/3 m^{-1}$ the mean time spent in the compartment
609 T3 is three months.

610 **Travel rate** In the focal data set, the proportion of children traveling to Southeast Asia varied
611 between 0 and 2% per year, with mean 0.7% per year. The travel rate is calculated as the treatment
612 rate. It is the solution of $P(V \leq 3) = 1 - e^{-3\nu} = 0.007$, such that $\nu = 0.002 m^{-1}$.

613 **Duration of travel** Most studies estimated the mean travel time to SEA is about 20 days (e.g.
614 Ruppé et al., 2015; Arcilla et al., 2017), corresponding to a rate of return from travel of $1.5 m^{-1}$.

615 **Post-travel period** As for the compartment T3, we chose $\psi_3 = 1/3 m^{-1}$ such that the mean
616 time spent in this compartment is three months.

617 **Force of infection during travel** Previous studies showed that 30 to 70% of travelers to SEA
618 are colonized by ESBL strains during travel (Paltansing et al., 2013; Ruppé et al., 2015; Kantele
619 et al., 2015; Reuland et al., 2016; Arcilla et al., 2017; Woerther et al., 2017). We assumed that
620 about 50% of the travelers are colonized during a 20-day travel (Ruppé et al., 2015). We further
621 assumed that the force of colonization of resistant strains did not depend on their colonization
622 type: $\lambda_{RC} = \lambda_{RP} = \lambda_R$.

623 A simple model of infection can inform on the force of colonization while traveling. Consider
624 a cohort of individuals that travel to Asia during 20 days. None of them initially carry MRE.
625 The dynamics of MRE carriage during travel is given by: $dX_R[t]/dt = \lambda_R(1 - X_R[t])$ (neglecting
626 clearance during travel) where X_R is the density of travelers carrying MRE during travel, λ_R is
627 the force of colonization during travel (assumed to be independent of X_R and t). Solving for the
628 differential equation with $X_R[0] = 0$, we obtain $X_R[t] = e^{-\lambda_R t}(e^{\lambda_R t} - 1)$. Further using $t = 20$ and
629 looking for $X_R[20] = 0.5N$ and solving for λ_R , we obtain $\lambda_R \approx 0.035 d^{-1} \approx 1.1 m^{-1}$

630 No information is available concerning the force of colonization by sensitive strains during
631 travel. As a baseline, we assumed that $\lambda_S \approx \lambda_R$.

632 **Clearance and colonization rates of sensitive strains** We estimated these parameters using
633 an external dataset on the turnover of *E. coli* strains in 127 Swedish infants followed longitudinally
634 from birth (Nowrouzian et al., 2003, 2005; Östblom et al., 2011). The infants were followed at 3
635 days, 1 week, 2 weeks, 4 weeks, 2 months, 6 months, 12 months after birth. At each visit,
636 *E. coli* colonies were isolated on Drigalski agar from faecal samples. As detailed in Östblom
637 et al. (2011), one to six colonies with different morphologies were isolated, typed with Random
638 Amplified Polymorphic DNA (RAPD) profiling and genotyped with several PCRs. Here, we used

639 the phylogroup of these strains obtained from Clermont typing (Clermont et al., 2000). Phylogroup
640 B2 was associated with a longer duration of carriage than others (Nowrouzian et al., 2005; Östblom
641 et al., 2011). Thus, we identified "colonizer" and "persistent" types to non-B2 and B2 strains. We
642 used a Bayesian approach to estimate the colonization and clearance rates depending on both the
643 colonization status of the host and on the phylogroup of the strains.

644 *Overview of the model fitted to longitudinal data*

645 We described the strain turnover within infants by a continuous time, discrete-state Markov chain
646 model. We defined the strains as 0 ($0 \equiv C \equiv \text{non-B2}$) or 1 ($1 \equiv P \equiv \text{non-B2}$). We considered as
647 variables the frequency of empty hosts, hosts colonized by a single strain, and hosts colonized by
648 two strains. Colonization by more than two strains only occurred twice, and these two timepoints
649 were removed from our analysis. There were therefore six variables representing the system: 1
650 for empty hosts, 2 for the single colonizations, 3 for the co-colonizations. Transitions between
651 colonization states occurred in three ways:

- 652 • colonization by one of the strains happening at rates $\lambda_0, \lambda_1, \lambda_{00}, \lambda_{01}, \lambda_{10}, \lambda_{11}$. These rates
653 account for both the transmission rate and the frequency of the colonizing strain in the
654 community. For co-colonization, the first index represents the strain already present in the
655 host, and the second index represents the colonizing strain.
- 656 • clearance of one of the strains happening at rates $\mu_0, \mu_1, \mu_{00}, \mu_{01}, \mu_{10}, \mu_{11}$. For clearance of
657 co-colonized individuals, the first index represents the strain that remains, and the second
658 index represents the strain that is cleared.
- 659 • direct replacement of one of the strains by another happening at rates ν_{01}, ν_{10} . The second
660 index represents the strain that replaces.

661 A 6×6 transition matrix \mathbf{A} described the rates of transitions between host colonization states.
662 The probability of a specific observed change from state i to state j in an infant, over an interval
663 of duration Δt , was given by $\exp(\mathbf{A}\Delta t)_{i,j}$. The probability of observed succession of states in an
664 infant was the product of these probabilities. Finally, the likelihood—the probability of the dataset
665 given the parameters—was given by the product of all infant probabilities.

666 Our aim was to use MCMC to estimate the posterior distribution of the 14 parameters:

$$\{\lambda_0, \lambda_1, \lambda_{00}, \lambda_{01}, \lambda_{10}, \lambda_{11}, \mu_0, \mu_1, \mu_{00}, \mu_{01}, \mu_{10}, \mu_{11}, \nu_{01}, \nu_{10}\}$$

667 After initial fits of the model where strains were considered as all equivalent, we used exponential
668 priors with means (in months⁻¹):

- 669 • $0.18 m^{-1}$ for simple colonizations λ_0, λ_1
- 670 • $0.066 m^{-1}$ for co-colonizations $\lambda_{00}, \lambda_{01}, \lambda_{10}, \lambda_{11}$
- 671 • $0.078 m^{-1}$ for clearance in single colonization μ_0, μ_1
- 672 • $0.234 m^{-1}$ for clearance in co-colonizations $\mu_{00}, \mu_{01}, \mu_{10}, \mu_{11}$
- 673 • $0.00192 m^{-1}$ for replacements ν_{01}, ν_{10}

674 We ran an MCMC algorithm for 2×10^6 iterations and retained only the last 1×10^6 iterations
675 to estimate the posterior distribution of parameters, after visually checking convergence of the
676 algorithm.

677 *Estimation of clearance rates*

678 We used the mean posterior distribution of the six clearance rates (see below for the transmission
679 rates), which were estimated to:

$$\begin{aligned}\bar{\mu}_0 &= 0.145 m^{-1} \\ \bar{\mu}_1 &= 0.0677 m^{-1} \\ \bar{\mu}_{00} &= 0.723 m^{-1} \\ \bar{\mu}_{01} &= 0.0978 m^{-1} \\ \bar{\mu}_{10} &= 0.308 m^{-1} \\ \bar{\mu}_{11} &= 0.340 m^{-1}\end{aligned}$$

These parameters are related to the parameters of our model following:

$$\begin{aligned}\bar{\mu}_0 &= \gamma_{S_C,1} \\ \bar{\mu}_1 &= \gamma_{S_P,1} \\ \bar{\mu}_{00} &= \gamma_{S_C,1}(1+d) \\ \bar{\mu}_{01} &= \gamma_{S_C,1}(1+d)(1-\epsilon) \\ \bar{\mu}_{10} &= \gamma_{S_P,1}(1+d)(1-\epsilon) \\ \bar{\mu}_{11} &= \gamma_{S_P,1}(1+d)\end{aligned}$$

where d measures the additional clearance from co-colonized hosts (such that $\gamma_{k,2} = \gamma_{k,1}(1-d)$) ($k \in \{S, P\}$) and ϵ measures niche differentiation (see main text). We used a linear model to estimate the $\gamma_{S_C,1}$, $\gamma_{S_P,1}$, d and ϵ (the four model parameters) from the mean of the posterior distributions using

$$\log \bar{\boldsymbol{\mu}} = \log \gamma_{S_C,1} \mathbf{X}_{\gamma, S_C} + \log \gamma_{S_P,1} \mathbf{X}_{\gamma, S_P} + \log(1+d) \mathbf{X}_d + \log(1-\epsilon) \mathbf{X}_\epsilon$$

680 where $\bar{\boldsymbol{\mu}}$ is the vector of the mean of the posterior for each of the clearance parameters, the $\mathbf{X}_{i,k}$
681 are binary vectors with value depending on whether $\bar{\mu}_i$ contains the corresponding factor k . The
682 parameters $\gamma_{S_P,1}$, $\gamma_{S_C,1}$, d and ϵ can be directly obtained from the estimated coefficients of the
683 linear model. Solving this linear model, we thus obtained $\gamma_{S_P,1} = 0.06$, $\gamma_{S_C,1} = 0.15$, $d = 4.0$ and
684 $\epsilon = 0.65$. These estimates result in the clearance parameters presented in Table 1.

685 *Transmission rates to uncolonized hosts*

686 We used the mean posterior distribution of the six transmission rates, divided by the frequency of
687 strain 0 (colonizers) or 1 (persisters) in the community, to estimate the transmission rates:

$$\begin{aligned}\bar{\beta}_0 &= 0.459 m^{-1} \\ \bar{\beta}_1 &= 0.335 m^{-1} \\ \bar{\beta}_{00} &= 0.300 m^{-1} \\ \bar{\beta}_{01} &= 0.155 m^{-1} \\ \bar{\beta}_{10} &= 0.106 m^{-1} \\ \bar{\beta}_{11} &= 0.167 m^{-1}\end{aligned}$$

These parameters are related to the parameters of our model following:

$$\begin{aligned}\bar{\beta}_0 &= \beta_{S_C,1} \\ \bar{\beta}_1 &= \beta_{S_P,1} \\ \bar{\beta}_{00} &= \beta_{S_C,1}(1-d_\beta) \\ \bar{\beta}_{01} &= \beta_{S_C,1}(1-d_\beta)(1+\epsilon_\beta) \\ \bar{\beta}_{10} &= \beta_{S_P,1}(1-d_\beta)(1+\epsilon_\beta) \\ \bar{\beta}_{11} &= \beta_{S_P,1}(1-d_\beta)\end{aligned}$$

where d_β measures the reduced transmission to already colonized hosts and ϵ_β measures niche differentiation acting on transmission. We used a linear model to estimate the $\beta_{S_C,1}$, $\beta_{S_P,1}$, d_β and ϵ_β (the four model parameters) from the mean of the posterior distributions using

$$\log \bar{\beta} = \log \beta_{S_C,1} \mathbf{X}_{\beta,S_C} + \log \beta_{S_P,1} \mathbf{X}_{\beta,S_P} + \log(1 - d_\beta) \mathbf{X}_d + \log(1 + \epsilon_\beta) \mathbf{X}_\epsilon$$

688 where $\bar{\beta}$ is the vector of the mean of the posterior for each of the transmission parameters, the $\mathbf{X}_{i,k}$
689 are binary vectors with value depending on whether $\bar{\beta}_i$ contains the corresponding factor k . The
690 parameters $\beta_{S_P,1}$, $\beta_{S_C,1}$, d and ϵ_β can be directly obtained from the estimated coefficients of the
691 linear model. Solving this linear model, we thus obtained $\beta_{S_P,1} = 0.360 m^{-1}$, $\beta_{S_C,1} = 0.427 m^{-1}$,
692 $d_\beta = 0.6$. As the term corresponding to niche differentiation on transmission was not significant
693 in the linear model, and in accordance with another study, we considered there was no niche
694 differentiation on transmission ($\epsilon_\beta = 0$).

695 The inferred transmission rates in the Swedish cohort were not large enough to reach the
696 observed prevalence of *E. coli* in our French cohort, perhaps because of differences in epidemiology
697 between Sweden and France. Furthermore, these transmission rates together with the inferred
698 clearance rates led to large difference in competitive ability between persisters and colonizers.
699 We therefore modified the transmission rates to better fit our data. The transmission rates to
700 uncolonized hosts were instead computed to ensure that the P- and C- types (roughly) have the
701 same R_0 and that the expected frequency of uncolonized hosts was (roughly) $S^* = 1.7\%$ as
702 observed in our data. Precisely, we solved:

$$\frac{\beta_{S_C,1}}{\gamma_{S_C,1}} = \frac{\beta_{S_P,1}}{\gamma_{S_P,1}}$$
$$S^* = (\gamma_{S_C,1} + \gamma_{S_P,1}) / (\beta_{S_C,1} + \beta_{S_P,1})$$

703 The second equation corresponds to a rough approximation for the expected frequency of un-
704 colonized hosts. Solving these two equations for $\beta_{S_C,1}$ and $\beta_{S_P,1}$ results in $\beta_{S_C,1} = 8.74 m^{-1}$ and
705 $\beta_{S_P,1} = 3.60 m^{-1}$ as presented in Table 1. We finally used the inferred effect of colonization on
706 transmission rates value of , estimated at $d_\beta = 0.6$ to compute the values of $\beta_{S_C,2} = 3.5 m^{-1}$ and
707 $\beta_{S_P,1} = 1.44 m^{-1}$. The final transmission parameters are presented in Table 1.

708 Finally, note that the data from the 127 Swedish infants did not support the mechanism of direct
709 strain replacement: we estimated the mean posterior of these parameters to $\nu_{01} = 0.0055 m^{-1}$ and
710 $\nu_{10} = 0.0055 m^{-1}$.

711 S4 Metropolis-Hastings (MH) algorithm with adaptive sampling

712 In the following, we describe the MH algorithm used to obtain the MCMC chains.

713 Let be:

- 714 • $P_{R,i}$ the vector of parameter values at iteration i
- 715 • L_i the likelihood of $P_{R,i}$
- 716 • Σ_P the covariance matrix between parameters
- 717 • U the number of iterations to be performed between two updates of the covariance matrix.
- 718 We used $U = 500$.

719 Initialization

- 720 • $P_{R,0}$ a set of parameters drawn randomly in the respective prior distributions
- 721 • Σ_P a diagonal matrix with diagonal elements corresponding to the initial variances of the
- 722 parameters (we used 10^{-5})

723 The algorithm then proceeds as follow

- 724 • if i is a multiple of U , we update the covariance matrix to optimize the exploration of the
- 725 parameter space:
 - 726 – Determine the acceptance rate a since the last update as $1 - N(\text{Duplicate in } \{P_{R,k}\}_{k \in [i-U+1, i]})/U$
 - 727 – Get the number N_u of unique elements in the chain $\{P_{R,k}\}_{k \in [i-U+1, i]}$.
 - 728 – if $N_u = 1$ (no proposal was accepted during the last U iteration), we reduce the covari-
 - 729 ance matrix to $\Sigma_P = \Sigma_P/\gamma$, where we chose $\gamma = 10$.
 - 730 – if $a > 0.5$ (the acceptance rate is too large) we expand the covariance matrix to $\Sigma_P =$
 - 731 $\gamma \times \Sigma_P$.
 - 732 – if $a \geq 0.05$ (the acceptance rate is too small), we calculate the covariance matrix $\Sigma_{P,U}$
 - 733 of the chain of unique elements in $\{P_{R,k}\}_{k \in [i-U+1, i]}$ and set $\Sigma_P = \Sigma_{P,U}/(10 \times \gamma)$
 - 734 – if $a < 0.05$, we reduce the covariance matrix $\Sigma_P = \Sigma_P/\gamma$
- 735 • else
 - 736 – proposal = $P_{R,i} + \delta$ with δ drawn in a centered multivariate normal distribution with
 - 737 covariance matrix Σ_P
 - 738 – If each element of the proposal is within the non-zero interval of the prior distributions
 - 739 calculate the acceptance ratio as $\alpha = \mathcal{L}(\text{proposal})/\mathcal{L}(P_{R,i})$ where \mathcal{L} denotes likelihood,
 - 740 draw a random value x in a Uniform distribution on $[0, 1]$. If $x < \alpha$ the proposal
 - 741 is accepted: $P_{R,i+1} = \text{proposal}$ and $L_{i+1} = \mathcal{L}(\text{proposal})$, else the proposal is rejected:
 - 742 $P_{R,i+1} = P_{R,i}$ and $L_{i+1} = L_i$.
 - 743 – If an element of the proposal falls outside of prior, the proposal is rejected $P_{R,i+1} = P_{R,i}$
 - 744 and $L_{i+1} = L_i$.

745 **S5 MCMC convergence analysis**

746 We ran five independent MCMC chains with initial conditions sampled randomly in the prior
747 distributions. The MCMC chains were ran for 250,000 iterations. The convergence of the MCMC
748 chains was verified using functions (see below) provided in the coda R-package (Plummer et al.,
749 2006).

Table S4: Sample size adjusted for the autocorrelation (rounded to the nearest integer)

	chain 1	chain 2	chain 3	chain 4	chain 5	all combined
m_x	355	444	359	378	367	1901
$\delta_{\beta,R,1}$	691	800	626	525	444	3085
$\delta_{\beta,R,2}$	724	678	671	560	550	3183
$\delta_{\gamma,R,1}$	601	674	671	618	593	3157
$\delta_{\gamma,R,2}$	625	711	585	705	595	3222

Table S5: Gelman and Rubin's convergence diagnostic (implemented in R-package coda)

	m_x	$\delta_{\beta,R,1}$	$\delta_{\beta,R,2}$	$\delta_{\gamma,R,1}$	$\delta_{\gamma,R,2}$
point estimate (upper 95%CI)	1.10 (1.01)	1.01 (1.03)	1.02 (1.04)	1.01 (1.03)	1.02 (1.05)




Figure S2: Gelman-Rubin convergence plots. A: m_x , B: $\delta_{\beta,R,1}$, C: $\delta_{\beta,R,2}$, D: $\delta_{\gamma,R,1}$, E: $\delta_{\gamma,R,2}$

750 S6 Sensitivity of the inference to the model assumptions

751 We investigated the sensitivity of our inference to two alternative scenarios. For brevity, we present
752 only the posterior distributions obtained for each alternative scenario. Mostly, we found that our
753 main results qualitatively hold. The main effects of the alternative scenarios considered here are
754 on the estimate of the cost of resistance on transmission to uncolonized hosts, as we present below.

755 First, we assumed that the transmission rate of R-strains increases when hosts are under anti-
756 biotic treatment (Fig.S3). This scenario models strong competitive release during antibiotic
757 treatment (e.g. Smith et al., 2021). Precisely, we assumed that, in the compartment T (hosts
758 under treatment), $\beta_{R_k,i}^T = 5\beta_{R_k,i}^L$, where $L \in \{U, T_3, SEA, SEA_3\}$ and where $i \in \{1, 2\}$ and
759 $k \in \{P, C\}$. In this scenario, we obtained a relatively sharp estimate of a strong cost of resis-
760 tance on transmission to uncolonized hosts (Fig.S3A), in contrast to the reference scenario (Fig.
761 3). Thus, assuming strong competitive release was counterbalanced by inferring a strong cost of
762 resistance on transmission to uncolonized hosts.

763 Second, we modelled the case where transmission and clearance did not depend on density.
764 Precisely, transmission and clearance rates from co-colonized hosts were the same as those from
765 single-colonized hosts: $\beta_{xx} = \beta_x$ and $\gamma_{xx} = \gamma_x$, with $x \in \{R_k, S_l\}$ and $k, l \in \{C, P\}$. The posterior
766 distributions were similar to those obtained in the reference model (Fig.S4).




Figure S3: Posterior distribution under the assumption of strong competitive release during treatment. For all panels: colored curves represent the posterior distribution for each MCMC chain. The thick black curves is the posterior for all chains pooled. The vertical lines are the mean of the overall posterior distribution. Shaded area: 95% CI.




Figure S4: Posterior distribution under the assumption of density independent transmission and clearance rates. For all panels: colored curves represent the posterior distribution for each MCMC chain. The thick black curves is the posterior for all chains pooled. The vertical lines are the mean of the overall posterior distribution. Shaded area: 95% CI.

767 **S7 Model dynamics and comparison of the two-strain model with the**
768 **four-strain model**

769 **Two-strain model** We initially considered the dynamics of resistant (R) and sensitive (S) strain,
770 without genetic structuring. This model can be retrieved from the model presented in the main
771 text (considering additional genetic structuring with persistent and colonizer strains) by assuming
772 $\beta_{SC,1} = \beta_{SP,1} = \bar{\beta}_S$ and $\gamma_{SC,1} = \gamma_{SP,1} = \bar{\gamma}_S$. The results of the inference were similar to those we
773 obtained with the main model (Fig. S5). However, the model allowed coexistence in a narrower
774 range of parameters, especially for treatment rate (Fig. S6). Moreover, in the two-strain model
775 the dynamics to equilibrium was very slow, contrasting with the observed dynamics (Fig. S7).




Figure S5: Posterior distributions after inference for the two strain model. Setting and parameters similar to Fig. 3.




Figure S6: Sensitivity of the frequency of resistance to the treatment rate in the community predicted by the four-strain model (dark red, including genetic structuring as in main text) and the two-strain model (dark blue, without genetic structuring). All other parameters as in Table 1 and mean inferred values from the posterior distributions.




Figure S7: Dynamics of R frequency predicted by the two-strain and four-strain model and comparison with observed dynamics (as in Fig. 2). Red: four-strain model with genetic structuring (main text). Pink: two-strain model (without genetic structuring).

776 label of figure S7 : time in years

777 **Dynamics of R frequency** Expanding the model to include genetic structuring along the
778 persistence-colonization trade-off (Morel-Journel et al., 2025) partially resolved the above issues.
779 Coexistence between sensitive and resistant strains was allowed for a wide range of treatment rates
780 (Fig. S6). Assuming that the R strain was initially brought by travelers in a resistance-free commu-
781 nity, the dynamics of R frequency to equilibrium was also faster in the four-strain model (compare
782 red and pink in Fig. S7), though still slower than the observed one (Fig. S7). Adding genetic struc-
783 turing increased negative-frequency dependence selection on the resistance locus (through linkage
784 with the locus underlying within-host persistence, Fig. S8). Indeed, we found a strong association
785 between the loci determining antibiotic resistance and within-host persistence. Resistance is more
786 beneficial in persistent genotypes, which are more likely to be exposed to antibiotics (Lehtinen
787 et al., 2017). Resistance was strongly associated with persistence, whereas sensitivity was strongly
788 associated with colonization (Fig. S8).




Figure S8: Strain dynamics following the introduction of resistance by travelers at $t = 0$. A: sensitive strains. B: resistant strains. Same parameters as in Table 1.

789 S8 Supplementary figures




Figure S9: Correlation plot for the parameters in P when all MCMC chains are pooled.




Figure S10: Goodness of fit of the model. Histograms show the distribution of the frequencies of each type of hosts predicted by the model. The dashed-red vertical line show the frequencies of each type of hosts observed in the data set. The solid lines show the 95% CI for the observed frequencies, assuming that the count for each type of hosts is drawn in a binomial distribution $B(n,p)$ with n = number of the corresponding type of host observed and p = the observed frequency of the host type.




Figure S11: Frequency of ESBL as a function of age in *E. coli* infections in European hospitals. We used data from the ECDC on the frequency of resistance to in *E. coli* isolates in invasive infections (blood, cerebrospinal fluid). We fitted to these data a logistic model for resistance status as a function of year as factor, type of patient (inpatient or outpatient), and age category. We show the predicted resistance for an inpatient infected in 2019, as a function of age category, with 95% confidence intervals. The dashed line is for the [0-4] age category.

References

- 790
- 791 Alizon, S., De Roode, J. C., and Michalakakis, Y. (2013). Multiple infections and the evolution of
792 virulence. *Ecology letters*, 16(4):556–567.
- 793 Andersson, D. I. (2006). The biological cost of mutational antibiotic resistance: any practical
794 conclusions? *Current opinion in microbiology*, 9(5):461–465.
- 795 Arcilla, M. S., van Hattem, J. M., Haverkate, M. R., Bootsma, M. C., van Genderen, P. J.,
796 Goorhuis, A., Grobusch, M. P., Lashof, A. M. O., Molhoek, N., Schultsz, C., et al. (2017).
797 Import and spread of extended-spectrum β -lactamase-producing enterobacteriaceae by interna-
798 tional travellers (combat study): a prospective, multicentre cohort study. *The Lancet infectious
799 diseases*, 17(1):78–85.
- 800 Bezabih, Y. M., Sabiiti, W., Alamneh, E., Bezabih, A., Peterson, G. M., Bezabhe, W. M., and
801 Roujeinikova, A. (2021). The global prevalence and trend of human intestinal carriage of esbl-
802 producing escherichia coli in the community. *Journal of Antimicrobial Chemotherapy*, 76(1):22–
803 29.
- 804 Birgy, A., Levy, C., Bidet, P., Thollot, F., Derkx, V., Béchet, S., Mariani-Kurkdjian, P., Cohen,
805 R., and Bonacorsi, S. (2016). Esbl-producing escherichia coli st131 versus non-st131: evolution
806 and risk factors of carriage among french children in the community between 2010 and 2015.
807 *Journal of Antimicrobial Chemotherapy*, 71(10):2949–2956.
- 808 Blanquart, F. (2019). Evolutionary epidemiology models to predict the dynamics of antibiotic
809 resistance. *Evolutionary applications*, 12(3):365–383.
- 810 Blanquart, F., Lehtinen, S., and Fraser, C. (2017). An evolutionary model to predict the frequency
811 of antibiotic resistance under seasonal antibiotic use, and an application to streptococcus pneu-
812 moniae. *Proceedings of the Royal Society B: Biological Sciences*, 284(1855):20170679.
- 813 Blanquart, F., Lehtinen, S., Lipsitch, M., and Fraser, C. (2018). The evolution of antibiotic resis-
814 tance in a structured host population. *Journal of The Royal Society Interface*, 15(143):20180040.
- 815 Bui, T. M. H., Hirai, I., Ueda, S., Bui, T. K. N., Hamamoto, K., Toyosato, T., Le, D. T., and
816 Yamamoto, Y. (2015). Carriage of escherichia coli producing ctx-m-type extended-spectrum
817 β -lactamase in healthy vietnamese individuals. *Antimicrobial agents and chemotherapy*,
818 59(10):6611–6614.
- 819 Castanheira, M., Simner, P. J., and Bradford, P. A. (2021). Extended-spectrum β -lactamases:
820 An update on their characteristics, epidemiology and detection. *JAC-antimicrobial resistance*,
821 3(3):dlab092.
- 822 Chatterjee, A., Modarai, M., Naylor, N. R., Boyd, S. E., Atun, R., Barlow, J., Holmes, A. H.,
823 Johnson, A., and Robotham, J. V. (2018). Quantifying drivers of antibiotic resistance in humans:
824 a systematic review. *The Lancet Infectious Diseases*, 18(12):e368–e378.
- 825 Clermont, O., Bonacorsi, S., and Bingen, E. (2000). Rapid and simple determination of the
826 escherichia coli phylogenetic group. *Applied and environmental microbiology*, 66(10):4555–4558.
- 827 Cobey, S., Baskerville, E. B., Colijn, C., Hanage, W., Fraser, C., and Lipsitch, M. (2017). Host
828 population structure and treatment frequency maintain balancing selection on drug resistance.
829 *Journal of The Royal Society Interface*, 14(133):20170295.
- 830 Colijn, C., Cohen, T., Fraser, C., Hanage, W., Goldstein, E., Givon-Lavi, N., Dagan, R., and
831 Lipsitch, M. (2010). What is the mechanism for persistent coexistence of drug-susceptible and
832 drug-resistant strains of streptococcus pneumoniae? *Journal of The Royal Society Interface*,
833 7(47):905–919.

- 834 Collignon, P., Beggs, J. J., Walsh, T. R., Gandra, S., and Laxminarayan, R. (2018). Anthropolog-
835 ical and socioeconomic factors contributing to global antimicrobial resistance: a univariate and
836 multivariable analysis. *The Lancet Planetary Health*, 2(9):e398–e405.
- 837 Cotto, O., Armand-Lefevre, L., Matheron, S., Ruppé, E., and Blanquart, F. (2023). Within-host
838 density and duration of colonization of multidrug-resistant enterobacterales acquired during
839 travel to the tropics. *bioRxiv*, pages 2023–03.
- 840 Davies, N. G., Flasche, S., Jit, M., and Atkins, K. E. (2019). Within-host dynamics shape antibiotic
841 resistance in commensal bacteria. *Nature ecology & evolution*, 3(3):440–449.
- 842 de Lastours, V., Chopin, D., Jacquier, H., d’Humières, C., Burdet, C., Chau, F., Denamur, E., and
843 Fantin, B. (2016). Prospective cohort study of the relative abundance of extended-spectrum-beta-
844 lactamase-producing escherichia coli in the gut of patients admitted to hospitals. *Antimicrobial
845 agents and chemotherapy*, 60(11):6941–6944.
- 846 Duong, V., Lambrechts, L., Paul, R. E., Ly, S., Lay, R. S., Long, K. C., Huy, R., Tarantola, A.,
847 Scott, T. W., Sakuntabhai, A., et al. (2015). Asymptomatic humans transmit dengue virus to
848 mosquitoes. *Proceedings of the National Academy of Sciences*, 112(47):14688–14693.
- 849 Emons, M., Blanquart, F., and Lehtinen, S. (2025). The evolution of antibiotic resistance in europe,
850 1998–2019. *PLoS pathogens*, 21(4):e1012945.
- 851 Fraser, C., Hollingsworth, T. D., Chapman, R., de Wolf, F., and Hanage, W. P. (2007). Variation in
852 hiv-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. *Proceedings
853 of the National Academy of Sciences*, 104(44):17441–17446.
- 854 Gagliotti, C., Balode, A., Baquero, F., Degener, J., Grundmann, H., Gur, D., Jarlier, V., Kahlme-
855 ter, G., Monen, J., Monnet, D., et al. (2011). Escherichia coli and staphylococcus aureus: bad
856 news and good news from the european antimicrobial resistance surveillance network (ears-net),
857 formerly ears), 2002 to 2009. *Eurosurveillance*, 16(11):20–24.
- 858 Godijk, N. G., Bootsma, M. C., van Werkhoven, H. C., Schweitzer, V. A., de Greeff, S. C., Schof-
859 felen, A. F., and Bonten, M. J. (2022). Does plasmid-based beta-lactam resistance increase e.
860 coli infections: Modelling addition and replacement mechanisms. *PLoS Computational Biology*,
861 18(3):e1009875.
- 862 Harmand, N., Federico, V., Hindre, T., and Lenormand, T. (2019). Nonlinear frequency-dependent
863 selection promotes long-term coexistence between bacteria species. *Ecology Letters*, 22(8):1192–
864 1202.
- 865 Hu, Y., Matsui, Y., and W. Riley, L. (2020). Risk factors for fecal carriage of drug-resistant
866 escherichia coli: a systematic review and meta-analysis. *Antimicrobial Resistance & Infection
867 Control*, 9:1–12.
- 868 Jacopin, E., Lehtinen, S., Débarre, F., and Blanquart, F. (2020). Factors favouring the evolution
869 of multidrug resistance in bacteria. *Journal of the Royal Society Interface*, 17(168):20200105.
- 870 Jacquier, H., Assao, B., Chau, F., Guindo, O., Condamine, B., Magnan, M., Bridier-Nahmias, A.,
871 Sayingoza-Makombe, N., Moumouni, A., Page, A.-L., et al. (2023). Faecal carriage of extended-
872 spectrum β -lactamase-producing escherichia coli in a remote region of niger. *Journal of Infection*.
- 873 Johnson, J. R., Clabots, C., Porter, S. B., Bender, T., Johnston, B. D., and Thurs, P. (2022).
874 Intestinal persistence of colonizing escherichia coli strains, especially st131-h 30, in relation to
875 bacterial and host factors. *The Journal of Infectious Diseases*, 225(12):2197–2207.

- 876 Kachalov, V. N., Nguyen, H., Balakrishna, S., Salazar-Vizcaya, L., Sommerstein, R., Kuster, S. P.,
877 Hauser, A., Abel zur Wiesch, P., Klein, E., and Kouyos, R. D. (2021). Identifying the drivers
878 of multidrug-resistant klebsiella pneumoniae at a european level. *PLoS computational biology*,
879 17(1):e1008446.
- 880 Kantele, A., Lääveri, T., Mero, S., Vilkinan, K., Pakkanen, S. H., Ollgren, J., Antikainen, J., and
881 Kirveskari, J. (2015). Antimicrobials increase travelers' risk of colonization by extended-spectrum
882 betalactamase-producing enterobacteriaceae. *Clinical Infectious Diseases*, 60(6):837–846.
- 883 Karanika, S., Karantanos, T., Arvanitis, M., Grigoras, C., and Mylonakis, E. (2016). Fecal colo-
884 nization with extended-spectrum beta-lactamase-producing enterobacteriaceae and risk factors
885 among healthy individuals: a systematic review and metaanalysis. *Reviews of Infectious Diseases*,
886 63(3):310–318.
- 887 Krishna, A., Tonkin-Hill, G., Morel-Journel, T., Bentley, S., Turner, P., Blanquart, F., and Lehti-
888 nen, S. (2025). Quantifying the effects of antibiotic resistance and within-host competition on
889 strain fitness in streptococcus pneumoniae. *bioRxiv*, pages 2025–03.
- 890 Lehtinen, S., Blanquart, F., Croucher, N. J., Turner, P., Lipsitch, M., and Fraser, C. (2017).
891 Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration
892 of carriage. *Proceedings of the National Academy of Sciences*, 114(5):1075–1080.
- 893 Lipsitch, M. (2001). The rise and fall of antimicrobial resistance. *Trends in microbiology*, 9(9):438–
894 444.
- 895 Lipsitch, M., Colijn, C., Cohen, T., Hanage, W. P., and Fraser, C. (2009). No coexistence for free:
896 neutral null models for multistrain pathogens. *Epidemics*, 1(1):2–13.
- 897 MacFadden, D. R., Fisman, D. N., Hanage, W. P., and Lipsitch, M. (2019). The relative impact of
898 community and hospital antibiotic use on the selection of extended-spectrum beta-lactamase-
899 producing escherichia coli. *Clinical Infectious Diseases*, 69(1):182–188.
- 900 Marc, A., Kerioui, M., Blanquart, F., Bertrand, J., Mitja, O., Corbacho-Monné, M., Marks, M.,
901 and Guedj, J. (2021). Quantifying the relationship between sars-cov-2 viral load and infectious-
902 ness. *Elife*, 10:e69302.
- 903 Martinson, J. N., Pinkham, N. V., Peters, G. W., Cho, H., Heng, J., Rauch, M., Broadaway, S. C.,
904 and Walk, S. T. (2019). Rethinking gut microbiome residency and the enterobacteriaceae in
905 healthy human adults. *The ISME journal*, 13(9):2306–2318.
- 906 Melnyk, A. H., Wong, A., and Kassen, R. (2015). The fitness costs of antibiotic resistance muta-
907 tions. *Evolutionary applications*, 8(3):273–283.
- 908 Morel-Journel, T., Lehtinen, S., Cotto, O., Amia, R., Clermont, O., Dion, S., Figueroa, C., Mar-
909 tinson, J., Ralaimazava, P., Duval, X., et al. (2023). Residence-colonization trade-off and niche
910 differentiation enable the coexistence of escherichia coli phylogroups in healthy humans. *bioRxiv*,
911 pages 2023–08.
- 912 Morel-Journel, T., Lehtinen, S., Cotto, O., Amia, R., Dion, S., Figueroa, C., Martinson, J. N.,
913 Ralaimazava, P., Clermont, O., Duval, X., et al. (2025). Residence-colonization trade-off and
914 niche differentiation enable coexistence of escherichia coli phylogroups in healthy humans. *The*
915 *ISME journal*, 19(1):wraf089.
- 916 Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Aguilar,
917 G. R., Mestrovic, T., Smith, G., Han, C., et al. (2024). Global burden of bacterial antimicrobial
918 resistance 1990–2021: a systematic analysis with forecasts to 2050. *The Lancet*, 404(10459):1199–
919 1226.

- 920 Nicolas-Chanoine, M.-H., Gruson, C., Bialek-Davenet, S., Bertrand, X., Thomas-Jean, F., Bert, F.,
921 Moyat, M., Meiller, E., Marcon, E., Danchin, N., et al. (2013). 10-fold increase (2006–11) in the
922 rate of healthy subjects with extended-spectrum β -lactamase-producing escherichia coli faecal
923 carriage in a parisian check-up centre. Journal of Antimicrobial Chemotherapy, 68(3):562–568.
- 924 Niehus, R., van Kleef, E., Mo, Y., Turlej-Rogacka, A., Lammens, C., Carmeli, Y., Goossens,
925 H., Tacconelli, E., Carevic, B., Preotescu, L., et al. (2020). Quantifying antibiotic impact on
926 within-patient dynamics of extended-spectrum beta-lactamase resistance. Elife, 9:e49206.
- 927 Nowrouzian, F., Hesselmar, B., Saalman, R., Strannegård, I.-L., Åberg, N., Wold, A. E., and
928 Adlerberth, I. (2003). Escherichia coli in infants’ intestinal microflora: colonization rate, strain
929 turnover, and virulence gene carriage. Pediatric research, 54(1):8–14.
- 930 Nowrouzian, F. L., Wold, A. E., and Adlerberth, I. (2005). Escherichia coli strains belonging to
931 phylogenetic group b2 have superior capacity to persist in the intestinal microflora of infants.
932 The Journal of infectious diseases, 191(7):1078–1083.
- 933 Olesen, S. W., Lipsitch, M., and Grad, Y. H. (2020). The role of “spillover” in antibiotic resistance.
934 Proceedings of the National Academy of Sciences, 117(46):29063–29068.
- 935 Östblom, A., Adlerberth, I., Wold, A. E., and Nowrouzian, F. L. (2011). Escherichia coli
936 pathogenicity island-markers, malx and usp and the capacity to persist in the infant’s com-
937 mensal microbiota. Applied and Environmental Microbiology.
- 938 Palmer, C., Bik, E. M., DiGiulio, D. B., Relman, D. A., and Brown, P. O. (2007). Development
939 of the human infant intestinal microbiota. PLoS biology, 5(7):e177.
- 940 Paltansing, S., Vlot, J. A., Kraakman, M. E., Mesman, R., Bruijning, M. L., Bernards, A. T.,
941 Visser, L. G., and Veldkamp, K. E. (2013). Extended-spectrum β -lactamase-producing enter-
942 obacteriaceae among travelers from the netherlands. Emerging infectious diseases, 19(8):1206.
- 943 Paterson, I. K., Hoyle, A., Ochoa, G., Baker-Austin, C., and Taylor, N. G. (2016). Optimising
944 antibiotic usage to treat bacterial infections. Scientific reports, 6(1):1–10.
- 945 Pennings, P. S. (2025). Explaining the stable coexistence of drug-resistant and-susceptible
946 pathogens: the resistance acquisition purifying selection model. Epidemics, page 100848.
- 947 Pereira, F. C. and Berry, D. (2017). Microbial nutrient niches in the gut. Environmental
948 microbiology, 19(4):1366–1378.
- 949 Perez, R. L., Chung The, H., Vignesvaran, K., Tan, W. C., Chua, M. S. H., Tan, E. Y., Peng, S. Y.,
950 Zhou, L., Singh, S. R., Yeung, W., et al. (2025). Transmission dynamics of escherichia coli se-
951 quence type 131 in households—a one health prospective cohort study. Nature Communications,
952 16(1):8455.
- 953 Pitout, J. D., Nordmann, P., Laupland, K. B., and Poirel, L. (2005). Emergence of enter-
954 obacteriaceae producing extended-spectrum β -lactamases (esbls) in the community. Journal
955 of antimicrobial chemotherapy, 56(1):52–59.
- 956 Plummer, M., Best, N., Cowles, K., and Vines, K. (2006). Coda: Convergence diagnosis and
957 output analysis for mcmc. R News, 6(1):7–11.
- 958 Raffelsberger, N., Buczek, D. J., Svendsen, K., Småbrekke, L., Pöntinen, A. K., Löhr, I. H.,
959 Andreassen, L. L. E., Simonsen, G. S., coli ESBL Study Group, N. E., Sundsfjord, A., et al.
960 (2023). Community carriage of esbl-producing escherichia coli and klebsiella pneumoniae: a
961 cross-sectional study of risk factors and comparative genomics of carriage and clinical isolates.
962 Msphere, 8(4):e00025–23.

- 963 Rahbé, E., Glaser, P., and Opatowski, L. (2024). Modeling the transmission of antibiotic-resistant
964 enterobacterales in the community: a systematic review. *Epidemics*, page 100783.
- 965 Rahbe, E., Valdano, E., Smith, D. R., Guillemot, D., Cauchemez, S., Glaser, P., and Opatowski,
966 L. (2025). Global dynamics of antibiotic resistance: a modeling study of the spread of endemic
967 and emerging resistance in e. coli. *medRxiv*, pages 2025–09.
- 968 Reuland, E., Sonder, G., Stolte, I., Al Naiemi, N., Koek, A., Linde, G., van de Laar, T.,
969 Vandenbroucke-Grauls, C., and van Dam, A. (2016). Travel to asia and traveller’s diar-
970 rhoea with antibiotic treatment are independent risk factors for acquiring ciprofloxacin-resistant
971 and extended spectrum β -lactamase-producing enterobacteriaceae—a prospective cohort study.
972 *Clinical Microbiology and Infection*, 22(8):731–e1.
- 973 Ruppé, E., Armand-Lefèvre, L., Estellat, C., Consigny, P.-H., El Mniai, A., Boussadia, Y., Goujon,
974 C., Ralaimazava, P., Campa, P., Girard, P.-M., et al. (2015). High rate of acquisition but short
975 duration of carriage of multidrug-resistant enterobacteriaceae after travel to the tropics. *Clinical*
976 *Infectious Diseases*, 61(4):593–600.
- 977 Ruppé, E., Lixandru, B., Cojocar, R., Büke, Ç., Paramythiotou, E., Angebault, C., Visseaux,
978 C., Djuikoue, I., Erdem, E., Burduniuc, O., et al. (2013). Relative fecal abundance of extended-
979 spectrum- β -lactamase-producing escherichia coli strains and their occurrence in urinary tract
980 infections in women. *Antimicrobial agents and chemotherapy*, 57(9):4512–4517.
- 981 Smith, D. R., Temime, L., and Opatowski, L. (2021). Microbiome-pathogen interactions drive epi-
982 demiological dynamics of antibiotic resistance: A modeling study applied to nosocomial pathogen
983 control. *Elife*, 10:e68764.
- 984 Spellberg, B. and Rice, L. B. (2019). Duration of antibiotic therapy: shorter is better. *Annals of*
985 *internal medicine*, 171(3):210–211.
- 986 Sundqvist, M., Geli, P., Andersson, D. I., Sjölund-Karlsson, M., Runehagen, A., Cars, H., Abelson-
987 Storby, K., Cars, O., and Kahlmeter, G. (2010). Little evidence for reversibility of trimethoprim
988 resistance after a drastic reduction in trimethoprim use. *Journal of antimicrobial chemotherapy*,
989 65(2):350–360.
- 990 Tängdén, T., Cars, O., Melhus, A., and Löwdin, E. (2010). Foreign travel is a major risk factor
991 for colonization with escherichia coli producing ctx-m-type extended-spectrum β -lactamases: a
992 prospective study with swedish volunteers. *Antimicrobial agents and chemotherapy*, 54(9):3564–
993 3568.
- 994 Van den Bunt, G., Liakopoulos, A., Mevius, D., Geurts, Y., Fluit, A. C., Bonten, M. J., Mughini-
995 Gras, L., and van Pelt, W. (2016). Esbl/ampc-producing enterobacteriaceae in households with
996 children of preschool age: prevalence, risk factors and co-carriage. *Journal of Antimicrobial*
997 *Chemotherapy*, page dkw443.
- 998 van der Bij, A. K. and Pitout, J. D. (2012). The role of international travel in the worldwide spread
999 of multiresistant enterobacteriaceae. *Journal of Antimicrobial Chemotherapy*, 67(9):2090–2100.
- 1000 Woerther, P.-L., Andremont, A., and Kantele, A. (2017). Travel-acquired esbl-producing enter-
1001 obacteriaceae: impact of colonization at individual and community level. *Journal of travel*
1002 *medicine*, 24(suppl_1):S29–S34.
- 1003 Woerther, P.-L., Burdet, C., Chachaty, E., and Andremont, A. (2013). Trends in human fecal
1004 carriage of extended-spectrum β -lactamases in the community: toward the globalization of ctx-
1005 m. *Clinical microbiology reviews*, 26(4):744–758.